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Abstract
Melanoma cells recruit host tissue to become a part of the activated tumour stroma. This
stromal microenvironment is similar to that seen in fibrotic tissue. CCN1 and CCN2 are
tightly spatiotemporally regulated matricellular proteins involved in development and wound
healing, and are abberantly expressed in fibrosis. Additionally they have been seen to be
abnormally highly expressed in several cancers, including melanoma. Recent evidence has
shown that deletion of CCN2 in the fibroblasts renders mice resistant to several models of
fibrosis. Given this, I tested the hypothesis that deletion of CCN1 and CCN2 from
fibroblasts could similarly impede the formation of the activated stromal microenvironment
in melanoma. I used B16F(10) murine melanoma cells and syngeneic C57 BL6 mice with a
tamoxifen-dependent conditional deletion of CCN1 or CCN2 in their fibroblasts. First I
determined that loss of CCN2 in the fibroblasts prevents the metastasis of melanoma to the
lungs of the mice, while loss of CCN2 in the tumour alone does not. Second I determined
that loss of CCN2 from the fibroblasts prevented the expression of myofibroblast marker
αSMA and reduced the expression of pluripotency marker SOX2. This loss of CCN2 was
accompanied by a reduced tumour vascularisation, and a reduction in tumour cell
vasculogenic mimicry. Finally I determined that loss of CCN1 in the fibroblasts results in
highly disorganized collagen in the skin, which results in reduced metastasis of the
melanoma cells. These observations were supported by in vitro experiments showing that
deletion of CCN1 or CCN2 from melanoma cells reduce their ability to invade through a
collagen basement membrane, and that deletion of CCN2 impedes the ability of melanoma
cells to form tubule networks in nutrient-deficient environments. The results presented here
suggest that CCN1 and CCN2 in the stromal microenvironment mediate the metastasis of
melanoma through different mechanisms, with CCN2 being required for the activated
stromal microenvironment and tumour vascularisation, and CCN1 being required for
formation of a stiff and organized collagen network that facilitates tumour cell invasion, and
thus they might both present novel targets for therapies to improve patient outcome.
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Chapter 1
1.1

Introduction

Melanoma, a cancer that develops from melanocytes, is the second most common
invasive cancer in young adults, and the incidence of diagnosis among this group is only
increasing (Reed, Brewer et al. 2012). Of all skin cancers, melanoma is the most likely to
metastasize making it the most likely to be fatal (Society 2013). In 2017 in the US and
Canada there will be an estimated 97,000 new cases of melanoma diagnosed, and 11,000
fatalities (Society 2013, Society 2017). Of the three types of skin cancer (basal cell
carcinoma, squamous cell carcinoma, and melanoma) it is the least common; it accounts
for only 4% of skin cancers, but its highly metastatic nature makes it so deadly that it
accounts for over 80% of skin cancer deaths (Miller and Mihm 2006).

1.1.1

Staging and Risk

Melanoma progresses through several stages as it develops, and the survival rate of
patients is highly variable based on the stage at which it is diagnosed. The current
staging system used to evaluate melanomas is the TNM staging system most recently
updated by the American Joint Committee on Cancer in 2009 (Balch, Gershenwald et al.
2009). The TNM system is named for the three factors measured: primary Tumour
characteristics (such as thickness, ulceration, and mitotic rate), presence or absence of
metastases in regional lymph Nodes, and presence or absence of distant Metastases
(Balch, Gershenwald et al. 2009). This system will remain in use until December 31st
2017 when the newly updated TNM system, which removes mitotic rate and puts more
emphasis on circulating lactate dehydrogenase (LDH) levels, is implemented (AJCC
2017). Proper staging is important in developing a prognosis for patients diagnosed. For
example, a patient diagnosed while the tumour is thin and has not metastasized has a 10year survival rate of 95%, while a patient with multiple regional lymph node metastases
has a 10-year survival rate of only 33% (Balch, Gershenwald et al. 2009).
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1.1.2

Progression and Metastasis

Under healthy conditions, melanocytes are found throughout the basal layer of the
epidermis at a 1:10 ratio with keratinocytes where they extend their dendrites between
keratinocytes to facilitate delivery of melanin (Cichorek, Wachulska et al. 2013). In
addition to their presence in the epidermis, melanocytes are also found in hair follicles,
the uveal tract of the eye, and in lesser numbers in several other tissues (Shain and
Bastian 2016). In the epidermis, each melanocyte and its associated keratinocytes are
known as an Epidermal-Melanin Unit (Haass and Herlyn 2005). In this state their
association with keratinocytes and their E-cadherin mediated cell-to-cell contacts regulate
their proliferation and prevent transformation; in fact, when melanocytes are grown in
monoculture they begin expressing surface markers consistent with those acquired during
tumourigenesis of melanoma, and these markers disappear when the cells are then cocultured with undifferentiated keratinocytes (Haass and Herlyn 2005). Typically
melanocytes will escape the control of their associated keratinocytes in two
circumstances: To divide, which occurs approximately twice a year, or as a result of a
mutation (Shain and Bastian 2016). These mutations can be familial (such as mutations
in CDKN2A) or somatic (such as mutations in NRAS or BRAF), but these mutations are
frequently insufficient to drive melanocytes transformation on their own, and require
additional mutations which are frequently acquired through UV exposure (Sample and
He 2017).
Once sufficient mutations are accumulated the affected melanocytes will undergo the first
stage of melanoma development in which they decouple from their associated
keratinocytes, allowing them to proliferate and form a benign nevus – also known as a
mole (Miller and Mihm 2006). The majority of nevi enter a senescence-like state in
which very few of the melanocytes within them are able to proliferate further until they
acquire further mutations, such as inactivating mutations of the p53 tumour-suppressor
gene (Miller and Mihm 2006, Shain and Bastian 2016). In this state the nevus is typically
symmetrical, smooth, evenly coloured, and does not penetrate the basement membrane
(Miller and Mihm 2006).
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Once a melanocyte within a benign nevus acquires sufficient mutations to escape its
senescence-like state, it progresses to the second stage of development and becomes a
dysplastic nevus. Typically at this stage the lesion becomes asymmetrical, with abnormal
colouration patterns and the melanocytes within it become irregularly and abnormally
shaped (Miller and Mihm 2006). While a benign nevus has very little proliferation once
its senescence-like state has set it, it is believed that dysplastic nevi engage in constant,
slow proliferation that is offset by attritional factors which are sometimes strong enough
to reverse the development of the lesion entirely (Shain and Bastian 2016).
The third stage, known as the radial growth phase is characterized by a cancerous
histological phenotype, rapid growth across the epidermis with only minor incursions
across the basement membrane, and constitutive activation of ERK signaling to drive
rapid clonal cell proliferation (Haass and Herlyn 2005, Miller and Mihm 2006, Shain and
Bastian 2016). Explanted cells from lesions in the radial growth phase, or any earlier
phase, are typically unable to produce colonies in soft agar, as they are typically reliant
on exogenous growth factors (Miller and Mihm 2006, Steck 2014). Since the cells are
largely unable to penetrate deeper than the basement membrane, surgical excision up to
this stage remains highly effective (Steck 2014).
Once the lesion breaches the basement membrane and begins to expand through
intradermal growth it has reached the vertical growth phase (Nesbit and Herlyn 1994,
Miller and Mihm 2006). This phase is characterized by a loss of E-cadherin expression,
increased N-cadherin expression, and increased αVβ3 integrin expression that results in
induction of MMP2 to break down the collagen of the basement membrane and BCL-2 to
prevent apoptosis in the absence of cell-cell contacts, allowing explanted cells to colonize
soft agar (Kuphal, Bauer et al. 2005, Miller and Mihm 2006, Shain and Bastian 2016).
Additionally, the shift from E-cadherin to N-cadherin expression allows melanoma cells
to interact with fibroblasts and vascular endothelial cells to better facilitate migration and
intravasation (Haass and Herlyn 2005). It has been theorized that this newfound ability
to communicate and attach to fibroblasts might be instrumental in facilitating the
transition from the radial growth phase to the vertical growth phase (Haass and Herlyn
2005). At this point the tumour is fully competent to invade and metastasize to distant
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organs, though continuing accumulation of mutations may speed this process (Steck
2014). Once metastasis to distant organs has occurred, the tumour has entered its final
stage and becomes metastatic melanoma.

1.1.3

Current Therapies

Despite major advances in therapies for other cancers, melanoma remains difficult to
manage. While other cancers are vulnerable to chemo- and radio-therapies, melanoma is
largely unaffected by these traditional standbys (Soengas and Lowe 2003). Treatment
with dacarbazine, temozolomide, or fotemustine have very low response rates (with
complete response in less than 5% of patients and most responses lasting only ~1.5
months) and toxic combinatorial treatments not showing any significant increase in
survival (Thompson, Scolyer et al. 2005, Palathinkal, Sharma et al. 2014). Surgical
excision is highly effective, but only when melanomas are caught early; while resection
of non-metastatic lesions provides an approximately 5-year survival rate of 90%, even the
presence of microsatellite metastases (discrete lesions greater than 0.05mm in diameter
separated from the primary lesion) decreases this survival rate from 90% to 36% (Homsi,
Kashani-Sabet et al. 2005, Cummins, Cummins et al. 2006). Although conventional
chemotherapies and surgical excision are of little use in late stage melanoma, there are
several promising therapies, primarily in two major categories: molecularly targeted
inhibitors (primarily targeting the BRAF mutation) and anti-angiogenic therapies.

1.1.3.1

BRAF inhibitors

BRAF is a protein kinase of the RAF family that functions downstream of RAS to help
stimulate cell growth and survival by phosphorylation of MEK to activate ERK (Chan,
Singh et al. 2017). In 2002, large-scale sequencing of genes in the RAS-RAF-MEKERK-MAPK pathway revealed a mutation in the BRAF gene that resulted in constitutive
activation of this pathway (Davies, Bignell et al. 2002). The vast majority (92%) of these
mutations were in the same codon: BRAFV600E, which prevents folding of BRAF in its
inactive state and instead results in a new conformation that has 10-12 fold increased
kinase activity (Davies, Bignell et al. 2002, DeLuca, Srinivas et al. 2008). Present in
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approximately 60% of melanomas, BRAF mutations drive melanoma progression from
the earliest stages, and even contribute to the formation of a benign nevus (Miller and
Mihm 2006). While it is insufficient on its own to generate a cancerous lesion, when a
melanocytes acquires secondary mutations BRAF becomes a major driver of disease
progression (Miller and Mihm 2006, DeLuca, Srinivas et al. 2008). Since the discovery
of the BRAFV600E mutation, several inhibitors of its activity have been developed. The
two most promising inhibitors are vemurafenib and dabrafenib, both of which have gone
through phase III clinical trials. Although they both show significant increases in both
overall and progression-free survival, they also have approximately 50% response rates,
and both only increased overall survival by ~4 months (DeLuca, Srinivas et al. 2008,
Lim, Menzies et al. 2017). Whereas intrinsic resistance to BRAF inhibition is only
present in approximately 10% of BRAFV600E mutant melanomas, acquired resistance is
rapidly acquired by almost all patients (Lim, Menzies et al. 2017). The exact mechanism
behind this resistance is still being studied, but potential mechanisms include expression
of splice variants with reduced inhibitor affinity, BRAF allele amplification,
overexpression of alternative RAF isoforms, and activation of alternative ERK signaling
pathways (Lim, Menzies et al. 2017). One of the side-effects of the inhibition of
BRAFV600E is a paradoxical activation of wild-type BRAF in non-mutant cells. This
has been shown to occur not only in wild-type BRAF melanomas, but also in the cancer
associated fibroblasts of the stroma which results in increased contractility and matrix
deposition (Hirata, Girotti et al. 2015). When BRAFV600E cells are grown in the
presence of cancer associated fibroblasts, or when plated on an ECM layered rigid
substrate they displayed BRAF inhibitor resistance that was disrupted by inhibition of
integrin β1 or FAK indicating that the stiff matrix created by activation of the fibroblasts
in the stroma was conferring BRAF resistance through an alternate ERK signaling
pathway that relied upon integrin-mediated attachment to ECM (Figure 1) (Hirata, Girotti
et al. 2015). Collectively, these data suggest that disruption of this activated, stiff matrix
might represent a strategy to overcome resistance to BRAF inhibitors.
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Figure 1-1 BRAF inhibition is overcome by alternate ERK signaling
by hyperactivated stroma
Cells driven by a BRAFV600E mutation are sensitive to BRAF inhibition
until they migrate to the hyperactivated stromal microenvironment. In this
microenvironment an alternate ERK signaling pathway stimulated by
integrin-mediated attachment to the ECM compensates for the inhibition of
BRAF.
Reprinted from (Hirata, Girotti et al. 2015)
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1.1.3.2

Immune therapy

As melanoma is an immunogenic tumour, it must develop methods of evading immune
responses in the host as the cancer progresses (Anderson, Stromnes et al. 2017, Pulluri,
Kumar et al. 2017). As such, therapies to increase the effectiveness of the body's
immune response have been developed to combat melanoma. Therapies such as high
dose interleukin-2 inducing proliferation in T cell populations have been developed, but
show limited efficacy and high rates of severe toxicity (Pulluri, Kumar et al. 2017). More
recently, however, targeted therapies such as immune checkpoint inhibition and adoptive
T cell therapy have been developed and show more promise. Adoptive T cell therapy is a
therapy in which T cells are isolated from a patient and expanded in vitro before being reintroduced back into the patient (Perica, Varela et al. 2015). While the cells are being
expanded in vitro they can be genetically engineered to recognize tumour-specific
antigens, but this process is extremely expensive as a new line of T cells must be
developed for each individual patient (Perica, Varela et al. 2015, Anderson, Stromnes et
al. 2017). Additionally, these T cells are still susceptible to the immunosuppressive
mechanisms developed by the tumour microenvironment (Figure 2). Activation of cancer
associated fibroblasts into an αSMA expressing phenotype results in increased deposition
of collagen-rich extracellular matrix which can act as a physical barrier preventing T cells
from reaching the tumour, secretion of C-X-C motif chemokine 12 which coats tumour
cells and prevents T cell infiltration, increased secretion of pro-inflammatory cytokines
that create an immunosuppressive microenvironment by recruiting regulatory T cells and
myeloid derived suppressor cells, as well as increasing the expression of programmed
cell death ligand 1 (PD-L1) in tumour cells and the cells of the stromal microenvironment
(Anderson, Stromnes et al. 2017, Frydenlund and Mahalingam 2017, Pulluri, Kumar et al.
2017). PD-L1 is a membrane-bound protein which serves as a checkpoint of selfidentification for the immune system by interacting with programmed cell death protein 1
(PD-1) on T cells to inhibit their activity (Frydenlund and Mahalingam 2017). Melanoma
cells expressing high levels of PD-L1 have been shown to provoke fewer anti-tumour
immune responses, and the expression of PD-L1 by stromal cells has been hypothesized
to contribute to immune resistance as well (Frydenlund and Mahalingam 2017).
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Figure 1-2 Immunosuppressive mechanisms of the activated tumour stroma
Tumour cells activate cancer associated fibroblasts (CAF), which produce a thick
extracellular matrix (ECM) and secrete CXCL12 that impede access of the T cells to
the tumour. Tumour cells secrete suppressive cytokines and chemokines that reduce
the proliferation and activity of T cells, as well as attract suppressive cells like
regulatory T cells and Tumour Associated Macrophages. Expression of inhibitory
ligands by both tumour and stromal cells reduce T cell activity.
Reprinted from (Anderson, Stromnes et al. 2017)
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One method of impairing the immunosuppressive defenses of melanoma has been the
inhibition of immune checkpoints like PD-1 or cytotoxic T-lymphocyte associated
protein 4 (CTLA-4), a protein that is expressed in response to increased T cell
proliferation and reduces immune response (Pulluri, Kumar et al. 2017). While these
therapies have shown the capacity to increase overall survival rates of patients with
advanced melanoma, they do not show universal efficacy with CTLA-4 antagonist
therapies showing a response rate of 15% and PD-1 antagonist therapies showing an
approximately 40% response rate (Emens, Ascierto et al. 2017, Pulluri, Kumar et al.
2017). These low response rates are likely due to the fact that T cells targeted by these
inhibitors are still subject to the immunosuppresive mechanisms detailed above
(Anderson, Stromnes et al. 2017). Additionally, immune checkpoint inhibitors are
expensive, with treatments potentially costing hundreds of thousands of dollars per
patient per year (Frydenlund and Mahalingam 2017).

1.1.3.3

Anti-angiogenic therapies

As avascular tumours are theoretically limited in size to ~2mm3, the development of
therapies that disrupt the vascular networks of tumours held great promise to not only
limit the growth of smaller tumours, but also cause regression of larger lesions (Zaki,
Basu et al. 2012, Maj, Papiernik et al. 2016). In light of this, a large variety of antiangiogenic therapies have been developed, most of which fall into three major categories:
monoclonal antibodies attacking the VEGF pathway (either anti-VEGF or anti-VEGFR),
decoy receptor VEGF-trap peptides, or small molecule tyrosine kinase inhibitors (Maj,
Papiernik et al. 2016). Despite effective inhibition of VEGF signaling resulting from
these therapies, no study has shown a significant increase in overall survival from antiangiogenic monotherapy (Felcht and Thomas 2015, Maj, Papiernik et al. 2016).
Additionally, while anti-VEGF therapy combined with chemotherapy in colorectal cancer
shows an increase in progression-free survival, different trials showed mixed results for
overall survival (Maj, Papiernik et al. 2016). Tumours exhibit two different patterns of
anti-angiogenic therapies: Intrinsic resistance, where the tumour fails to respond to
therapy immediately, or acquired resistance, where there is an initial response to therapy
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followed by a resurgence of tumour growth and progression (Bergers and Hanahan 2008,
Lupo, Caporarello et al. 2016, Maj, Papiernik et al. 2016).
The reasons the therapies fail are multi-factorial, with most intrinsic resistance stemming
from preexisting oncogenic activation of non-VEGF reliant pro-angiogenic pathways, the
presence of inflammatory cell-mediated protection of vasculature, and vascular co-option
while acquired resistance is typically driven by new activation of alternative (VEGFindependent) pro-angiogenic pathways, compensatory vasculogenic mimicry and
vascular co-option, increased progenitor cell recruitment from bone marrow, and vascular
normalization (Bergers and Hanahan 2008, Pastushenko, Vermeulen et al. 2014, Felcht
and Thomas 2015). In addition, even when the treatment is successful, long-term hypoxia
in the tumour increases genetic instability, vascular permeability, and triggers
paradoxically increased VEGF production (Lupo, Caporarello et al. 2016).
In preclinical data using a pancreatic neuroendocrine cancer model, mice that were
subjected to anti-VEGFR inhibition experienced a brief period of responsiveness to
therapy before tumours began to regrow (Bergers and Hanahan 2008). During tumour
regression, these tumours had regions of hypoxia which began to express high levels of
pro-angiogenic factors Fibroblast Growth Factor 1 (FGF1), FGF2, ephrin A1, ephrin A2,
and angiopoeitin 1, and the treatment of these tumours with an FGF-trap protein was able
to slow revascularization and tumour regrowth indicating that FGF is one part of the
mechanism by which these tumours acquire resistance to anti-angiogenic therapies
(Bergers and Hanahan 2008). Other studies have found similar pro-angiogenic factors
upregulated, with anti-VEGF therapies in human patients resulting in increased
expression of placental growth factor, FGF2, and interleukin 8 as well as persistent
upregulation of mTOR signaling (Maj, Papiernik et al. 2016). Additionally, untreated
late stage breast cancers show an increased tolerance for anti-VEGF therapy as well as
elevated expression of pro-angiogenic factors like FGF2, suggesting that in addition to
playing a role in acquired resistance these pathways are able to be activated and grant
intrinsic resistance as well (Bergers and Hanahan 2008). Similarly, in experiments
performed using anti-VEGF therapies in mouse models a heterogeneous response to
treatment was seen, where tumours with high levels of infiltrating inflammatory cells
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prior to treatment showed a reduced response, likely due to pro-angiogenic factors being
secreted by the inflammatory cells (Bergers and Hanahan 2008).
Another barrier to effective inhibition of angiogenesis in tumours stems from the fact that
sprouting and maturation are driven by competing signals: When VEGF is
overexpressed, a tumour will develop a large number of blood vessels, but this VEGF
expression will prevent the association of perivascular cells like pericytes which drive
vessel stability and maturation (Maj, Papiernik et al. 2016). When anti-VEGF therapies
block this overexpression, the vessels which have already been formed begin to recruit
perivascular cells and undergo a process known as vessel normalization, which leads to
increased vascular organization, decreased vessel permeability, increased vessel
diameter, and more reliable delivery of nutrients throughout the tumour (Helfrich and
Schadendorf 2011, Maj, Papiernik et al. 2016). Since the association of perivascular cells
protects these newly normalized vessels from anti-VEGF therapy-associated regression, it
also explains why tumours in highly vascularized tissues such as brain metastases and
cutaneous melanomas are more able to withstand anti-angiogenic therapies: A significant
portion of their vascular networks are formed by vascular co-option, in which they hijack
already mature vasculature which do not undergo regression when deprived of VEGF
(Felcht and Thomas 2015).
Anti-angiogenic therapies have also been associated with high levels of side-effects.
Complications from anti-VEGF antibody therapies include endocrine dysfunction,
cardiac toxicity, gastrointestinal perforation, thrombosis, and impaired wound healing
with tyrosine kinase inhibitors also showing malaise, fatigue, hypothyroidism, and
cardiac failure due to off-target kinase inhibition (Lupo, Caporarello et al. 2016, Maj,
Papiernik et al. 2016). Additionally, even in cases where the therapy is successful in
causing vascular regression it is possible that both antibody therapy and tyrosine kinase
inhibitors may promote metastasis by damaging vascular walls that normally serve as a
barrier to extravasation while simultaneously inducing a more invasive tumour cell
phenotype (Bergers and Hanahan 2008, Lupo, Caporarello et al. 2016).
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Tumour-host interactions

1.2

As a tumour develops it not only alters the cells carrying oncogenetic mutations, but also
begins to recruit host tissue cells to form an active stroma that participates in the
development and progression of the disease (Le Bitoux and Stamenkovic 2008). As the
tumour grows it begins to secrete cytokines that recruit and activate several different cells
types which develop into macrophages, mast cells, adipocytes, and carcinoma-associated
fibroblasts which begin to secrete cytokines, disrupt existing extracellular matrix, and
deposit new extracellular matrix in a fashion that can play a significant role in the
progression of the disease (Le Bitoux and Stamenkovic 2008).

1.2.1

Skin

While melanoma can arise from any pigmented tissue in the body, including mucous
membranes and the eye, the most common site for it to develop is the skin. Skin is
composed of four major layers: The epidermis, the dermis, a basement membrane that
separates them, and finally the hypodermis (Kanitakis 2002). Each of these is further
subdivided, and most melanomas arise from the epidermis.

1.2.1.1

The Epidermis

The epidermis serves as a barrier to protect the body from dehydration, toxins,
mechanical perturbation, and microorganism intrusion. In order to serve this purpose it is
avascular, stratified, and composed of four layers of epithelium which undergo
considerable transformation as they move from deep to superficial tissue (Simpson, Patel
et al. 2011).

1.2.1.1.1

Keratinocytes

The most common cells in the epidermis, keratinocytes (and the corneocytes to which
they will eventually differentiate), are produced in the stratum basale which is a single
layer of cells attached to the basement membrane between the epidermis and the dermis
(Kanitakis 2002). This layer of cells is composed of proliferating stem cells which
proliferate asymmetrically, with the daughter cell deeper in the tissue remaining a stem
cell and the superficial one being a keratinocyte which becomes part of the stratum
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spinosum (Kanitakis 2002, Proksch, Brandner et al. 2008). The cell polarity that allows
this asymmetry of proliferation is possible because of the strong attachment to the
basement membrane by hemidesmosomes (Kanitakis 2002, Simpson, Patel et al. 2011).
As keratinocytes differentiate off of the proliferating stem cells of the stratum basale,
they begin a process of differentiation which begins with large, polygonal cells with a
distinct nucleus and organelles and ends with completely squamous cells lacking both
nuclei and organelles (Simpson, Patel et al. 2011). This process progresses as the
keratinocytes move through each of the layers of the epidermis. Keratinocytes of the
stratum spinosum stop proliferating, are connected to each other by a strong network of
intracellular connections, and form a 5-15 cell thick layer. Cells are pushed superficially
by continually proliferating stem cells in the stratum basale, and as they move
superficially they are subjected to gradually increasing calcium concentrations which
eventually trigger differentiation (Bikle, Jiang et al. 2016). These differentiating cells
begin to produce lamellar bodies, which will eventually help form a barrier to hydrophilic
substances that helps prevent water loss through the skin (Kanitakis 2002, Proksch,
Brandner et al. 2008). As calcium continues to increase and the cells enter the stratum
granulosum, the lamellar bodies move from the Golgi where they are produced, and fuse
with the plasma membrane to release their contents into the extracellular matrix (Proksch,
Brandner et al. 2008). While this process occurs the keratinocytes begin to flatten out,
and form a layer 1-3 cells thick (Kanitakis 2002). Finally, in the stratum corneum the
cells differentiate from keratinocytes into corneocytes by degrading their major
organelles with lysosomal enzymes (Simpson, Patel et al. 2011). This layer is composed
of highly squamous cells which are crosslinked together in order to form the primary
barrier against chemicals and microbes, as well as allowing the cells to withstand
mechanical forces (Proksch, Brandner et al. 2008, Simpson, Patel et al. 2011).

1.2.1.1.2

Melanocytes

While 90-95% of cells within the epidermis are keratinocytes, there are several other
important cell types present throughout. Langerhans cells are present throughout the
epidermis, and within the stratum basale there are Merkel cells, lymphocytes, and
melanocytes (Kanitakis 2002). In most areas of the skin the stratum basale is made up of
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a 1:10 ratio of melanocytes to proliferating stem cells. Melanocytes are anchored to the
basement membrane, with dendrites extending up through the epidermis to form an
associated epidermal-melanin unit each consisting of a single melanocytes making
contact with 30-40 keratinocytes (Kanitakis 2002, Cichorek, Wachulska et al. 2013). The
epidermal-melanin unit has several important functions, with keratinocytes receiving
protection from UV irradiation from the melanin secreted by melanocytes and with
keratinocytes using both paracrine signaling and cell-cell adhesions with melanocytes to
regulate melanocytes proliferation (Haass, Smalley et al. 2005, Cichorek, Wachulska et
al. 2013). While in the epidermis melanocytes typically do not proliferate. This is
believed to be in large part due to cell-cell adhesions with keratinocyte progenitor cells
suppressing proliferation, as melanocytes grown in vitro display proliferative capacity
that is suppressed when co-cultured with undifferentiated keratinocyte progenitors
(Cichorek, Wachulska et al. 2013, Wang, Fukunaga-Kalabis et al. 2016). Due to this lack
of proliferation, combined with an accumulation of reactive oxygen species most humans
show a 10-20% decrease in number of epidermal melanocytes per decade over the age of
30, with older melanocytes becoming larger and more dendritic to reach more
keratinocytes (Cichorek, Wachulska et al. 2013).
In addition to control by cell-cell contact, keratinocytes can exert control over
melanocytes through paracrine signaling. This method of control is typically associated
with exposure of keratinocytes to UV radiation, which causes secretion of stem cell
factor, endothelin 1, and pro-inflamatory cytokines like interleukin 1 (Cichorek,
Wachulska et al. 2013, Wang, Fukunaga-Kalabis et al. 2016). These factors serve to
activate several signal transduction pathways, with stem cell factor activating mitogenactivated protein kinases and endothelin 1 activating protein kinase C to increase
transcription of genes associated with melanocyte dendricity and melanogenesis, and
interleukin 1β upregulating melanocytes expression of CCN3 which acts in an autocrine
fashion to enhance adhesion to the basement membrane of the epidermis (Cichorek,
Wachulska et al. 2013, Wang, Fukunaga-Kalabis et al. 2016). Melanocytes also receive
paracrine signals from dermal fibroblasts, who secrete stem cell factor and neuroregulin 1
to help alter melanocytes function (Cichorek, Wachulska et al. 2013).
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In addition to being found throughout the stratum basale, melanocytes can also be found
in hair follicles, mostly at the apex of the dermal papilla and in the sebaceous glands
associated with hair (Cichorek, Wachulska et al. 2013). Here melanocytes are found in
higher numbers, with a ratio that is usually closer to 1:5 than the 1:10 ratio found in most
of the epidermis (Haass and Herlyn 2005, Cichorek, Wachulska et al. 2013). While they
undergo a lot of the same processes, there are several key differences between
melanocytes found in the follicle. Unlike epidermal melanocytes there is considerable
turnover in follicular melanocytes, with all fully differentiated melanocytes undergoing
apoptosis every 3-8 years and being replaced by resident melanoblasts located
superficially in the follicle. Additionally, their melanogenesis is regulated independently
of UV exposure, with melanogenesis only taking place during the anagen phase when
hair is growing, and not during catagen or telogen phases where there is little to no
growth (Cichorek, Wachulska et al. 2013).
Between the epidermis and the dermis is the basement membrane, which is composed of
4 layers: First is a layer of keratin and plectin attached to the basal plasma membrane of
keratinocyte progenitor cells and melanocytes by hemidesmosomes, second is anchoring
filaments composed of laminins, third is a the lamina densa which is composed of
collagen IV and laminin V, and finally is the sub-basal lamina filamentous zone
composed of collagen VII fibres anchoring the basement membrane to the dermis
(Kanitakis 2002, Proksch, Brandner et al. 2008).

1.2.1.2

The Dermis

The dermis is a vascularized region composed primarily of large amounts of extracellular
matrix, fibroblasts, and macrophages (Kanitakis 2002). It is divided into two layers: the
papillary dermis, which lies just below the basement membrane and is named for
fingerlike dermal papillae it forms in order to increase surface area of attachment with the
basement membrane, and the reticular dermis (Kanitakis 2002). The papillary dermis
consists of loose connective tissue that supports capillary networks which deliver oxygen
and nutrients to both the dermis and the epidermis, as well as tactile sensors, while the
reticular dermis is characterized by thicker connective tissue which provides strength to
the dermis, and the presence of larger blood vessels which feed the capillaries of the
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papillary dermis (Kanitakis 2002, Oosterhoff, Sluijter et al. 2012). The reticular dermis
also houses the roots of hair follicles, along with sebaceous and sweat glands (Kanitakis
2002). The vast majority of the mass of the dermis is made up of collagen fibres (mainly
types I and III) with 90% of the fibres being collagen, providing the dermis with a high
tensile strength (Kanitakis 2002, Arora, Falto-Aizpurua et al. 2017). In addition to
collagen, elastin and elastic fibres are present (mostly in the reticular dermis), making up
another 2-4% of the dermis by mass, with the rest being composed of cells and a mixture
of glycoproteins and proteoglycans known as ground substance (Kanitakis 2002, Arora,
Falto-Aizpurua et al. 2017). The extracellular matrix of the dermis is undergoing
constant maintenance and has a high rate of turnover, with the synthesis of new
connective tissue being conducted by spindle shaped cells called fibroblasts (Kanitakis
2002, McAnulty 2007). Fibroblasts regulate the extracellular matrix of the dermis by
producing matrix metalloproteinases, which degrade extracellular matrix components,
and by producing the majority of extracellular matrix components themselves (McAnulty
2007). In addition to their role in maintaining healthy extracellular matrix, fibroblasts are
also key players in responding to tissue injury. When tissue is damaged, cytokines are
released that recruit fibroblasts to the wound to assist in deposition of new extracellular
matrix and they are activated into a myofibroblast phenotype that is characterized by
expression of α-smooth muscle actin stress fibers which allow them to assist with
contraction and closure of the wound (McAnulty 2007).
The deepest section of the skin is known as the hypodermis. It is mostly composed of
adipocytes surrounded by loose connective tissue, fibroblasts, nerves, and blood vessels,
and it helps with storage of energy, thermoregulation, and protection from mechanical
forces (Kanitakis 2002).

1.2.2

Collagen Fibril Assembly

Dermal collagen consists of a little less than 90% type I collagen, 10% type III collagen,
and approximately 2% type V collagen (Krieg and Aumailley 2011). Collagens are
transcribed and synthesized as α chains of procollagen monomers before undergoing
extensive post-translational modifications in the rough endoplasmic reticulum and Golgi
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apparatus involving the hydroxylation of specific prolyl and lysyl residues and
glycosylation of others (Kadler, Baldock et al. 2007, Krieg and Aumailley 2011). Prolyl
hydroxylation is required for each monomer to fold into a left-handed helix, at which
point three α chain monomers supercoil into a right-handed triple helix, which is then
stabilized with hydrogen bonds inside the rough endoplasmic reticulum (Mienaltowski
and Birk 2014, Bella 2016). Once this triple helix is properly formed the collagen
molecules are released from the endoplasmic reticulum and can enter the extracellular
space (Kadler, Baldock et al. 2007). Once outside the cell the collagen molecules can be
formed into fibrils through numerous mechanisms: They can self-assemble around
nucleators, they can be directed to assemble by cell-directed organizers, and their growth
can be controlled by regulator molecules and enzymes (Mienaltowski and Birk 2014,
Du, Pang et al. 2017).
While type I and type III collagen can self-assemble in vitro, it is only after considerable
lag and is not seen to occur in vivo, where despite production and secretion of type I and
III collagen molecules, they do not form into fibrils without type V collagen to act as a
nucleator (Mienaltowski and Birk 2014). In concert with nucleators, cells can direct the
assembly of fibrils by assembling fibronectin into fibrils using integrins, forming
fibronectin networks that contain binding sites that assist with collagen fibril assembly
(Mienaltowski and Birk 2014). Blocking the fibronectin binding sites, or alteration of
integrins that assemble the fibronectin organizer complex, can result in alterations to
collagen fibril assembly. Regulator molecules like small leucine-rich proteoglycans and
some non-fibril forming collagens are not necessary for the initiation of fibril assembly,
but can alter the rate at which collagen fibrils grow, and also the characteristics that result
from growth. Disruption of these regulators can result in abnormally large fibril
diameters which have functional defects (Mienaltowski and Birk 2014).
Once fibrils have begun to form, their maturation into a stable network is governed by a
balance of enzymatic activity. Fibrils are stabilized by the formation of intramolecular
and intermolecular cross-links after oxidative deamination by a class of enzymes called
lysyl oxidases, and hydroxylation by lysyl hydroxylases (Krieg and Aumailley 2011).
The key enzyme in mediating the hydroxylation of lysyl residues in type I collagen is
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lysyl hydroxylase 2, which is encoded by the gene PLOD2, with decreased levels of
PLOD2 expression in tumour stroma correlating with decreased lysine aldehyde-derived
crosslinks (Du, Pang et al. 2017). Additionally the extent of lysyl residue hydroxylation
can have effects on the circumference of the triple helical domain of collagens, resulting
in changes in fibril assembly (Mienaltowski and Birk 2014). Once collagen networks are
formed, matured, and stabilized they can be remodeled by the activity of matrix
metalloproteinases MMP1 and MMP13 (Krieg and Aumailley 2011, Moro, Mauch et al.
2014).

1.2.3

Fibrosis: Cancer as a wound that won’t heal

When tissue experiences an injury or insult it goes through several stages in attempting to
resolve the damage: Hemostasis (when the injury has caused bleeding), Inflammation,
Proliferation of new tissues, and finally Remodelling of the newly formed tissue
(Buganza Tepole and Kuhl 2013). In the case of cancer, however, the insult is not easily
resolved by these processes, and so the cancer cells persist, stimulating a wound healing
response that is unable to resolve (Horimoto, Polanska et al. 2012, Kalluri 2016). This
results in sustained inflammation, and the recruitment of a wide variety of cells to form
an activated stroma, similar to what occurs in fibrotic diseases like scleroderma. In fact,
activated tumour stroma and fibrosis are both characterized by high numbers of activated
fibroblasts and an increased deposition of extracellular matrix (Kalluri 2016). The link
between cancer and fibrosis is reinforced by the fact that co-morbidity of cancer and
scleroderma has been show to occur quite frequently with the incidence of melanoma
being 3.3 times as high among patients diagnosed with scleroderma as among the general
population (Videtic, Lopez et al. 1997, O'Byrne and Dalgleish 2001, Coussens and Werb
2002, Hill, Nguyen et al. 2003, Shah, Rosen et al. 2010, Franks and Slansky 2012). In
addition to this increased incidence, there is a notable temporal proximity between
diagnoses of cancer and fibroproliferative diseases, with almost 50% of breast cancer
diagnoses amongst scleroderma patients occurring very close to the diagnoses of
scleroderma itself (Shah, Rosen et al. 2010). There is considerable debate as to what is
causing this increased association of not only the incidence, but also time of onset
between cancer and fibroproliferative diseases. One theory is that the overactive
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fibroproliferative processes in diseases such as scleroderma not only lay down excessive
extracellular matrix which can lead to organ failure, but they also produce a tumour
stroma which is conducive to the progression of malignancy (O'Byrne and Dalgleish
2001, Rakoff-Nahoum 2006). Additionally, the inflammatory cascade produced by an
initial injury or insult produces high amounts of oxidative stress, resulting in the
production of reactive oxygen species that not only perpetuate the inflammatory cascade
but also cause DNA damage leading to DNA breaks, single base mutations, and genomic
instability which are known to lead to tumourigenesis (Le Bitoux and Stamenkovic 2008,
Elinav, Nowarski et al. 2013). Cytokines like tumour necrosis factor α, interleukin 1β,
and transforming growth factor (TGF)β1, that are elevated in the fibrotic
microenvironment, trigger signaling cascades that introduce mutations in the genes
encoding p53 and Myc which contribute to oncogenesis (Elinav, Nowarski et al. 2013).
These cytokines also induce nuclear factor-κB signaling, which increases proinflammatory, proliferative, and survival gene expression from both tumour and stromal
cells (Le Bitoux and Stamenkovic 2008, Kalluri 2016).
Once oncogenesis has occurred, a diverse tumour stroma is recruited, most importantly
including the recruitment of immune cells and the recruitment and activation of activated
cancer associated fibroblasts (CAFs) (Le Bitoux and Stamenkovic 2008, Horimoto,
Polanska et al. 2012, Kalluri 2016). Recruited immune cells play several roles, with
activated macrophages producing cytokines to increase inflammatory signaling
throughout the stroma, recruit additional immune cells like leukocytes, inhibit immune
response, increase pro-angiogenic signaling, and promote gene expression associated
with survival (Le Bitoux and Stamenkovic 2008). Additional immune cells recruited by
macrophages serve to amplify the signals secreted by macrophages, activate resident
fibroblasts, and secrete proteolytic enzymes which can reduce physical barriers to tumour
spread and cause the release of sequestered growth factors from the extracellular matrix
(Le Bitoux and Stamenkovic 2008, Horimoto, Polanska et al. 2012).
The activated fibroblasts of the tumour stroma have proven to be key drivers in the
progression of many different cancers. CAFs induce invasion of non-invasive cells in
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many cancer models by secreting matrix metalloproteinases, which help remodel stromal
matrix to increase stiffness and align extracellular matrix components to facilitate
invasion, and TGFβ, allowing improved adhesion of cancer cells to the extracellular
matrix: CAFs have also been shown to be highly migratory (Horimoto, Polanska et al.
2012, Kalluri 2016). Additionally, CAFs secrete tenascin C and periostin, which have
both been shown to be mediators of the development of a “cancer stem cell” phenotype
that is able to take root in distant organs after metastasis and form metastatic sites
(Horimoto, Polanska et al. 2012). CAFs are a highly heterogeneous population: although
there are several markers which are absent in inactivated normal fibroblasts, such as
fibroblast specific protein 1, vimentin, α-smooth muscle actin, PDGF receptor α and β,
these markers are neither exclusive to activated fibroblasts, nor expressed by all cancer
associated fibroblasts (Kalluri 2016). For example, fibroblast specific protein 1 also
identifies immune cells, vimentin is expressed widely in mesenchymally-derived cells,
and PDGF receptors are also present in the perivasculature (Kalluri 2016). This
heterogeneous pattern of marker expression pattern may simply reflect that CAFs are
likely to originate from a variety of different sources. Indeed, CAFs have been suggested
to arise from bone marrow-derived precursors, mesenchymal stem cells, endothelial cells,
resident fibroblasts, epithelial cells, pericytes, smooth muscle cells, and adipocytes
(Bhattacharyya, Wei et al. 2012, Horimoto, Polanska et al. 2012, Kalluri 2016). In
fibrotic diseases, recruitment and proliferation of these cell types has been induced
inflammatory cytokines, and differentiation has been seen to be caused by several
different mechanisms. Resident fibroblasts can be differentiated in to myofibroblasts by
TGFβ1 signaling or by mechanical strain being transduced through integrins (Koivisto,
Heino et al. 2014). Blocking integrins αvβ5 or αvβ3 in vitro is able to prevent this
differentiation, as is deletion if integrin β1 in vivo (Liu, Xu et al. 2010, Koivisto, Heino et
al. 2014). The protein Phosphatase and tensin homolog (PTEN), which inactivates proadhesive signaling and is frequently mutated in cancers, can suppress myofibroblast
differentiation of resident fibroblasts and loss of PTEN not only accelerates cancer
progression, but when it is deleted from fibroblasts in vivo it results in spontaneous
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generation of fibrosis (Horimoto, Polanska et al. 2012, Parapuram, Thompson et al.
2015). Damage to microvasculature has also been seen to cause pericyte differentiation
into myofibroblasts in patients with scleroderma, and in mouse models of fibrosis
myofibroblasts were observed to express pericyte/progenitor marker genes NG2 and
SOX2 (Rajkumar, Sundberg et al. 1999, Tsang and Leask 2015). Additionally, lineage
tracing revealed some fibrotic myofibroblasts are derived from dermal progenitor cells,
and the process requires expression of matricellular protein CCN2 which is highly
upregulated in fibrotic diseases (Liu, Herault et al. 2014, Tsang and Leask 2015).

1.2.4

Tumour vascularization

Tumour vascularization is essential for the progression, growth, and metastasis of any
tumour. Since oxygen can only diffuse approximately 100-150µm through tissue
avascular tumours are limited in the maximum size they can achieve (Felcht and Thomas
2015). While it has been estimated that an avascular tumour can reach up to 2-3mm3 in
volume, vascularization typically begins when a tumour reaches approximately 1mm3, or
the distance between two blood vessels is larger than 100-250µm (Helfrich and
Schadendorf 2011, Zaki, Basu et al. 2012). As tumours grow, they develop regions of
hypoxia which are either too far removed from vasculature, or which have had their
blood supply cut off when the vessels feeding them are occluded by the growing tumour
(Muz, de la Puente et al. 2015). Intratumoural hypoxia alters the balance between proand anti-angiogenic signals, primarily by signaling through the Hypoxia Inducible Factor
(HIF) pathway, triggering what is known as the “Angiogenic Switch” when proangiogenic signals are stronger than anti-angiogenic signals (Helfrich and Schadendorf
2011, Muz, de la Puente et al. 2015). This balance can also be altered by other factors
like mechanical stress, inflammation, or genetic mutation (Helfrich and Schadendorf
2011). Once this switch is flipped, there are 4 major forms of neovascularization that
take place within a tumour: sprouting angiogenesis, vascular co-option (where the
tumour will simply grow around an existing vessel and thus hijack it), vasculogenic
mimicry and mosaic vessels, and bone marrow-derived vasculogenesis (Pastushenko,
Vermeulen et al. 2014, Felcht and Thomas 2015).
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1.2.4.1

Mechanisms of neovascularization

Sprouting angiogenesis is a recapitulation of the angiogenesis that occurs during
development and wound healing in which the growth of new capillaries occurs starting
from existing vessels (Pastushenko, Vermeulen et al. 2014). Although there are many
factors that can trigger this process, the most predominant one is VEGF secretion from
the tumour. Not only does HIF signaling induce VEGF expression, but several
oncogenes can cause constitutive overexpression of VEGF by the tumour through MEK
activation, PI3K activation, NFκB activation, and ROS production (Pastushenko,
Vermeulen et al. 2014, Muz, de la Puente et al. 2015). When VEGF reaches the
endothelial cells of a blood vessel, it causes them to reduce their cell-cell contacts (which
help to keep endothelial cells quiescent and non-proliferative) with each other, increase
their mitogenesis, proliferation, survival, and migration signals (Zaki, Basu et al. 2012,
Mongiat, Andreuzzi et al. 2016). Once these cell junctions loosen, there is extravasation
of plasma proteins, which help serve as a scaffold for endothelial cell migration and
organization, and the initiation of a proteolytic cascade involving matrixmetalloproteases, which degrade both the basement membrane of the existing vessel and
the extracellular matrix between the endothelial cells and the source of VEGF secretion
resulting in both a path for endothelial cells to migrate through and release of bound proangiogenic factors (Zaki, Basu et al. 2012, Pastushenko, Vermeulen et al. 2014, Mongiat,
Andreuzzi et al. 2016). As the process progresses endothelial cells will migrate in a
specific pattern, with a polarized tip cell breaking off to migrate across the extracellular
matrix, followed by some rapidly proliferating stalk cells which will begin to form the
lumen of the new vessel, and lastly phalanx cells which have recruited perivascular cells,
like pericytes, through secretion of Transforming Growth Factor β, and PDGF to help
mature and stabilize them (Helfrich and Schadendorf 2011, Pastushenko, Vermeulen et
al. 2014, Felcht and Thomas 2015, Muz, de la Puente et al. 2015). The expression of
Angiopoietin-1 by perivascular cells binds to Tie-2 receptors on endothelial cells,
inducing quiescence (Helfrich and Schadendorf 2011).
In addition to sprouting angiogenesis melanoma makes great use of vascular co-option,
(Pastushenko, Vermeulen et al. 2014, Felcht and Thomas 2015). Vascular co-option is
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more prevalent in melanoma than some other cancers (for example breast cancer tends to
grow primarily through sprouting angiogenesis) and while this process occurs in the
primary tumour, it is especially prevalent in distant metastatic sites where the freshly
extravasated melanoma cells will grow around the existing vasculature (Felcht and
Thomas 2015). These newly co-opted vessels are typically more mature and stable than
newly formed vasculature within the tumour (Helfrich and Schadendorf 2011).
Both sprouting angiogenesis and vascular co-option are ways in which the tumour can
incorporate endothelial cells into its vascular network, but when that process proves
insufficient to meet nutrient and waste disposal needs of rapidly proliferating cells the
tumour can begin to reprogram its own cells to serve the same purpose in a process
known as vasculogenic mimicry (Pastushenko, Vermeulen et al. 2014, Felcht and
Thomas 2015). Vessels created by vasculogenic mimicry can either be tube structures
composed of either reprogrammed tumour cells or a mixture of endothelial cells and
tumour cells which closely resemble normal endothelial lined blood vessels, or they can
be patterned matrices consisting of collagens, heparin sulfate proteoglycans and laminins
that closely resemble the basement membrane of a blood vessel but which lack any
cellular lining (Pastushenko, Vermeulen et al. 2014, Pinto, Sotomayor et al. 2016). In
either case the melanoma cells lining them begin to express markers that are
characteristic of endothelial cells, such as CD31 or vascular endothelial (VE)-cadherin
(Pinto, Sotomayor et al. 2016). Additionally, both tubular and non-tubular examples of
vasculogenic mimicry have been shown to stain positive for periodic-acid Schiff (PAS)
stain, and contain red blood cells in histological sections, indicating that they are both
successful at conducting blood throughout the tumour (Pastushenko, Vermeulen et al.
2014, Pinto, Sotomayor et al. 2016).
Finally, new vasculature can be generated by recruitment of bone marrow-derived
progenitor cells which will be integrated into new vessels and differentiated into
endothelial cells by VEGF signaling (Pastushenko, Vermeulen et al. 2014, Felcht and
Thomas 2015, Muz, de la Puente et al. 2015). Several factors secreted by both tumour
and stromal components have been identified in the recruitment process, including
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VEGF, stromal derived factor-1, placental growth factor, stem cell factor, and
interleukin-6 (Bergers and Hanahan 2008, Maj, Papiernik et al. 2016).

1.2.4.2

Tumour vascular environment

Despite the formation of new vasculature, the oxygenation of intratumoural tissue is far
from consistent. Due to high levels of VEGF secretion by tumour cells, highly
heterogeneous makeup of vasculature, and periodic blood vessel occlusion tumours
contain areas of acute, chronic, and cycling hypoxia (Helfrich and Schadendorf 2011,
Muz, de la Puente et al. 2015)
Tumour hypoxia can come in three major forms, with different consequences for each:
acute hypoxia is a short term interruption in blood flow that is generally resolved in less
than 72 hours and triggers autophagy to allow cells to survive, induces spontaneous
metastasis and a more invasive phenotype; chronic hypoxia is a sustained state of low
oxygen availability which impairs DNA repair systems and increases accumulation of
DNA damage, leading to increased genomic instability and mutagenesis; cycling hypoxia
is frequently caused by short-term occlusion of blood vessels, and results in recurring
fluctuations in tissue oxygen levels which has been shown to increase reactive oxygen
species production, and increase tumour cell survival and aggressiveness (Muz, de la
Puente et al. 2015, Lupo, Caporarello et al. 2016).
In addition to occlusion of vasculature, hypoxia can result from the disorganized and
largely immature vasculature found within a tumour. While high levels of VEGF
secretion by tumour cells is helpful in generating new vasculature, it does not subside
when the new vasculature has been established, and so the normal blood vessel
phenotype that includes pericytes instructing endothelial cells to form tight junctions to
prevent fluid leak does not occur: Continuous VEGF expression acts on endothelial cells
preventing them from entering their quiescent state, and prevents pericyte coverage of
vessels by disrupting PDGF signaling (Greenberg, Shields et al. 2008, Helfrich and
Schadendorf 2011). Additionally, this non-quiescent endothelial cell phenotype results in
increased vascular permeability, which increases intra-tumoural interstitial pressure and
augments hypoxia (Zaki, Basu et al. 2012).
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1.2.5

CCN Proteins

The CCN proteins are a family of matricellular proteins named for the first three
members (CYR61, CTGF, and NOV) characterized by a highly conserved modular
structure consisting of an insulin-like growth factor binding domain, a Von Willebrand
factor type C domain, a thrombospondin type 1 domain, and a C-terminal domain (Leask
and Abraham 2006). Matricellular proteins are non-structural, secreted proteins that
modulate cellular reactions to external stimuli, and as such the CCN proteins are highly
spatiotemporily regulated (Leask and Abraham 2006, Jun and Lau 2011). Their activity
is primarily mediated through direct binding to adhesion receptors like integrins and
heparin sulphate proteoglycans (HSPGs), but they can also bind to other receptors like
lipoprotein receptor-related proteins (LRPs) and modulate the expression and
bioavailability of a wide variety of growth factors, cytokines and matrix
metalloproteinases (Chen and Lau 2009, Jun and Lau 2011). CCN protein expression is
sensitive to signals from growth factors, UV radiation, hypoxia, mechanical forces, and
inflammatory cytokines, allowing them to be regulated in response to a wide variety of
stimuli (Chen and Lau 2009). Each protein's function is highly context dependent:
CCN1, CCN2, and CCN3 promote apoptosis in fibroblasts when bound as cell adhesion
substrates, but when they bind to endothelial cells they serve as protection against
apoptosis due to different integrin expression patterns between the cell types (Chen and
Lau 2009, Jun and Lau 2011). CCN1-3 are pro-angiogenic in vivo, and promote cell
adhesion, migration, proliferation, and tubule formation of endothelial cells in vitro
(Leask and Abraham 2006). Given these pro-angiogenic roles it is unsurprising that
CCN1 is required for the formation of a cardiovascular system during embryonic
development, and mice lacking CCN2 display severe vascular defects (Jun and Lau 2011,
Mongiat, Andreuzzi et al. 2016).
CCN1 and CCN2 are upregulated in wound healing, with CCN2 being released from
platelets and both CCN1 and CCN2 being transcriptionally upregulated in response to
TGFβ signaling. During wound healing they act as adhesion substrates for platelets and
inflammatory cells, as well as modulating TGFβ activity on fibroblasts and unmasking
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the cytotoxic effects of TNFα to facilitate the apoptosis of fibroblasts (Jun and Lau
2011).
Both CCN1 and CCN2 are also highly upregulated during fibrosis, but while CCN1 and
CCN2 have been shown to have similar functions in vitro, it has been proposed that they
have different functions in vivo, with CCN1 inducing a senescence-like phenotype in
while CCN2 potentiates TGFβ signaling (Leask and Abraham 2006, Jun and Lau 2011).
CCN2 expression in fibroblasts is essential for the development of fibrosis, and mice with
Ccn2 deleted from their fibroblasts are resistant to both bleomycin-induced skin fibrosis
and PTEN deficiency-induced fibrosis (Liu, Shi-wen et al. 2011, Liu, Parapuram et al.
2013).
Given the similarities between activated tumour stroma and fibrosis, the overexpression
of CCN1 and CCN2 during fibrosis, and the pro-angiogenic activities of CCN1 and
CCN2, the following study investigates the role of CCN1 and CCN2 in the progression of
metastatic melanoma. My hypothesis is that CCN1 and CCN2 play different, but
complementary roles in the progression of melanoma, with CCN2 promoting the
vascularization of the tumour and facilitating the development of a collagen producing
activated stroma, and CCN1 promoting the processing and stabilization of produced
collagen.
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Chapter 2

2

CCN2 Expression by Tumour Stroma is Required for
Melanoma Metastasis

2.1

Introduction

Melanoma is the second most common invasive cancer in young adults, and the incidence
of diagnosis among this group is increasing (Reed, Brewer et al. 2012). Of skin cancers,
melanoma is the most likely to metastasize making it the most likely to be fatal:
Approximately 5% of patients diagnosed with metastatic melanoma survive for 5 years
after diagnosis, whereas patients with no metastases have a 5 year survival rate
approaching 90% (Cummins, Cummins et al. 2006).
Melanocytes, protective cells found in the skin, are subjected to assault by UV radiation
on a routine basis, and thus require a strong resistance to apoptosis. Unfortunately this
resistance is retained when melanocytes progress into melanoma, leaving the cancer
largely unaffected by chemotherapy and radiotherapy (Soengas and Lowe 2003,
Cummins, Cummins et al. 2006, Gray-Schopfer, Wellbrock et al. 2007). Given this high
resistance to conventional therapies and the effectiveness of surgical excision in the
absence of metastasis (Cummins, Cummins et al. 2006), discovering methods of
preventing metastasis is vital to increasing patient survival.
For melanoma to metastasize, tumour cells must migrate through the extracellular matrix,
which is built by cells in the stromal microenvironment. Following the degradation of
the extracellular matrix, tumour cells must migrate by forming new adhesive sites closer
to their destination and degrading old adhesive sites further away. The formation and
degradation of these sites are governed by integrins, and the communication between
cells and their surrounding matrix is mediated by a class of non-structural secreted
proteins known as matricellular proteins (Steeg 2006).
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It has long been recognized that expression of the CCN family of matricellular proteins,
is highly associated with certain cancers (Bleau, Planque et al. 2005, Perbal 2013). CCN2
(formerly known as connective tissue growth factor, CTGF) is a member of the CCN
family of matricellular proteins, which act primarily in two ways; by directly binding to
adhesion receptors like integrins, and by acting as co-factors for other regulatory
molecules (Chen and Lau 2009, Perbal 2013). Abnormal expression patterns of CCN
proteins have been associated with progression of breast, prostate and pancreatic cancers
(Xie, Nakachi et al. 2001, Yang, Tuxhorn et al. 2005, Dornhofer, Spong et al. 2006, Sha
and Leask 2011, Wong and Rustgi 2013) and overexpression of CCN2 has been
associated with malignant melanoma (Sha and Leask 2011). CCN2 expression can also
be stimulated in surrounding tissues by the inflammatory response caused by tumour
formation (Coussens and Werb 2002, Leask and Abraham 2006, Wong and Rustgi 2013).
While these observations suggest that CCN2 plays a role in the metastasis of melanoma,
the majority of studies involving the role of CCN proteins in cancer have only correlated
expression levels of the proteins with tumour progression without incorporating loss of
function studies. Recently CCN2 was shown to be regulated by the Hippo pathway in
melanoma cell lines (Nallet-Staub, Marsaud et al. 2014). Moreover, an antibody to
CCN2 was shown to revert established metastatic melanoma in a murine model (Finger,
Cheng et al. 2014); however, the mechanism underlying CCN2 action is unclear. In
particular, neither the relative roles of tumour- or stroma- derived CCN2 in melanoma
metastasis, nor the downstream effectors of CCN2, are clear.
In this report, we use a syngeneic B16F(10) murine melanoma model (cells derived from
C57 BL6 mice) (Wack, Kirst et al. 2002) and C57 BL6 mice lacking CCN2 in fibroblasts
to investigate the differential roles of cancer cell versus niche-derived CCN2 in
melanoma invasion and metastasis.

2.2

Methods

2.2.1 Cell Culture and Western Blotting
B16(F10) murine melanoma cells were purchased (ATCC) and cultured in high glucose
Dulbecco's Modified Eagle's Medium (DMEM), 10% fetal bovine serum (FBS) and 1%
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antibiotic/antimycotic solution (Invitrogen). C8161 and c81-61 cells were provided by
Mary Hendrix, and experiments using them were performed at the University of Alberta.
Cells were cultured until confluence prior to harvesting for mRNA or protein extraction.
Where indicated, cells were treated with 10µM Bisindolylmaleimide I (BIM), a pan-PKC
inhibitor (EMD Millipore), for 6 hours prior to RNA extraction. Cells were cultured until
confluence prior to harvesting for mRNA or protein extraction. CCN2 levels were
detected by co-incubating cultures with 50µg/mL sodium heparin (Sigma). Sodium
heparin was included to prevent rapid internalization and degradation of CCN2 via LRP1
as endogenous CCN2 is known to be rapidly degraded by mouse cells through this
mechanism (Segarini, Nesbitt et al. 2001). 1mL conditioned culture media was collected
for every treatment, and total protein were concentrated using methanol/chloroform
precipitation as previously described (Friedman, Hoving et al. 2009). Periostin protein
levels were assessed by extraction of total protein [using ice-cold TG lysis buffer (20 mM
Tris- HCl [pH 8], 1% Triton X-100, 10% glycerol, 137 mM NaCl, 1.5 mM MgCl2, 1 mM
EGTA, 50 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 20 µM
leupeptin, 10 µg of aprotinin ml-1)]. The concentration of protein was detected (Pierce)
and equal amounts of protein (100 g) were subjected to SDS/PAGE on a 4-12%
gradient gel (Invitrogen). Gels were then blotted onto nitrocellulose (BioRad) and CCN2
was detected using a goat anti-CCN2 antibody (1:200 dilution, Santa Cruz) followed by a
HRP-conjugated anti-goat antibody (1:2000; Jackson), a chemiluminescent detection kit
(Pierce) and X-Ray film (Kodak). Alternatively, Periostin was detected using a rabbit
anti-POSTN (1:1000 dilution; Santa Cruz) followed by a HRP-conjugated anti-rabbit
antibody (1:2000; Jackson), a chemiluminescent detection kit (Pierce) and X-Ray film
(Kodak). When indicated, cells were transfected with CTGF (CCN2) shRNA Lentiviral
or control shRNA Lentiviral Particles (Santa Cruz) using polybrene and selected for
using puromycin as described by the manufacturer (Santa Cruz), or with CTGF (CCN2)
siRNA or control siRNA using Lipofectamine 2000 transfection kit (Thermo Fisher
Scientific) as per manufacturer instructions.
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2.2.2 Real Time RT-PCR
B16(F10) murine melanoma cells were grown in high glucose DMEM containing 10%
FBS until 75% confluence after which the media was replaced with low glucose DMEM
containing 0.5% FBS and grown for 24 hours. RNA was harvested using Trizol
(Invitrogen) and used for Real-Time RT-PCR. 25 ng of RNA was reverse transcribed and
amplified using TaqMan Assays on Demand (Applied Biosystems) in a 15μl reaction
containing primers for mouse CCN2 and POSTN (Assays on Demand; Applied
Biosystems) and 6-carboxyfluroscein labelled TaqMan MGB probe. Reverse
Transcriptase One-Step Mastermix was added to samples and the ABI Prism 7900 HT
sequence detector (Applied Biosystems) was used according to manufacturer’s
instructions to detect amplified sequences. Samples were run in triplicate, expression
values were standardized to control values from EUK18S primers using the Ct
method. Statistical analysis was done using one way ANOVA and Tukey’s post-hoc test
on GraphPad.

2.2.3 Expression Profiling
Expression profiling was performed as described in prior publications (Guo, Carter et al.
2011, Guo, Carter et al. 2011) All sample labeling and processing was handled at the
London Regional Genomics Centre (Robarts Research Institute, London, Ontario,
Canada; http://www.lrgc.ca). Briefly, RNA quality was assessed on an Agilent 2100
Bioanalyzer (Agilent Technologies Inc.) and the RNA 6000 Nano kit (Caliper Life
Sciences) before 5.5 μg of single-stranded cDNA was synthesized from 200 ng of total
RNA, end-labeled, and hybridized, for 16 hours at 45 °C, to Human Gene 1.0 ST arrays.
GeneChips were scanned with the GeneChip Scanner 3000 7G and probe level (.CEL
file) data were generated using Affymetrix Command Console v3.2.4. Probes were
summarized to gene level data in Partek Genomics Suite v6.6 (Partek) using the RMA
algorithm. Experiments were performed twice, and fold changes and P-values were
generated using analysis of variance in Partek. Genes that significantly changed (at least
1.5 fold change, P-value <0.05) in response to CCN2 knockdown were compiled and
exported into DAVID (http://david.abcc.ncifcrf.gov/) for further analysis.
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2.2.4 Immunohistochemistry
Tissue was stained for CCN2 and Periostin using the Vectastain ABC Kit (Vector
Laboratories). Briefly, sections (0.5 μm) were cut using a microtome (Leica), collected
on Superfrost Plus slides (Fisher Scientific), de-waxed in xylene, and rehydrated by
successive immersion in descending concentrations of alcohol. Antigen retrieval was
performed by immersing slides in Na-citrate solution (pH 6.0) for 30 minutes at 98°C.
After cooling, slides were rinsed, and non-specific binding was blocked by incubation
with diluted normal serum. Sections were incubated with primary antibodies in diluted
normal serum (1:100 goat anti-CCN2, or 1:100 rabbit anti-POSTN), followed by
incubation with biotinylated secondary antibody solution and Vectastain ABC Reagent.
After incubations, the sections were incubated in ImmPACT DAB peroxidise substrate
(Vector Laboratories) and counterstained with hematoxylin.

2.2.5 In vitro Invasion Assay
10,000 Parental untreated, CCN2 shRNA, and Control shRNA B16(F10) cells were
seeded in growth medium containing 0.5% FBS (and 5μg/mL puromycin hydrochloride
for shRNA cells) onto a transwell filter insert with a pore size of 8 μm coated with 100μL
of 10μg/mL purified bovine collagen (Advanced Biosystems) as previously described
(Chen 2005). The transwell filter insert was suspended in a plate filled with growth
medium containing 10% FBS (to create a chemotactic incentive to invade) and allowed to
incubate at 37°C for 24 hours. After incubation all excess collagen and non-invasive
cells were removed from the inside of the transwell filter insert. The remaining cells
were fixed in methanol, and stained with 1μg/mL DAPI to allow for counting with
microscopy.

2.2.6 Animals
Mice possessing a tamoxifen-dependent Cre recombinase under the control of a
fibroblast-specific regulatory sequence from the proα2(I) collagen gene (Zheng, Zhang et
al. 2002) were crossed with mice homozygous for a conditional CCN2 allele to generate
Cre/CCN2 heterozygote mice, which were mated to generate mice hemizygous for Cre
and homozygous for CCN2. Animals used for experiments were genotyped by
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polymerase chain reaction (PCR) as described previously (Zheng, Zhang et al. 2002, Liu,
Shi-wen et al. 2011). To delete CCN2 (CCN2-/-) in fibroblasts, 3-week-old mice were
given intraperitoneal injections of tamoxifen suspension (0.1 ml of 10 mg/mL 4hydroxitamoxifen, Sigma) over 5 days. Littermate mice of identical genotype were
injected with corn oil and were used as controls (CCN2fl/fl). All animal protocols were
approved by the animal care committee at the University of Western Ontario.

2.2.7 In vivo Tumour Growth and Metastasis
Subconfluent melanoma cells in the exponential growth phase were harvested by
exposure to 0.25% trypsin/0.02% EDTA solution, resuspended in serum-free DMEM at a
concentration of 3300 cells/µL, and 330,000 cells were injected subcutaneously into the
right flank of each mouse. Upon appearance of a palpable tumour the volume of the
tumour was measured daily using calipers and the following equation: Tumour Volume
(mm3) = 1/2(Length of Longest Tumour Dimension) x (Length of Narrowest Tumour
Dimension)2. Tumour growth was evaluated over the course of 14 days, and mice were
euthanized on the 14th day. After euthanasia the lungs and tumour were collected from
the mice and fixed in a 4% paraformaldehyde solution. After fixation, tissues were
processed, embedded in paraffin, and prepared for histological sectioning. Lung sections
were stained with hematoxylin and eosin (H&E; Fisher Scientific) to locate dense
metastatic foci. Three non-serial sections per lung were examined. To examine
macroscopic metastasis in the lungs, tumours were allowed to grow for 21 days, and
collected lungs were stained with Bouin’s solution and rinsed with 70% ethanol to
visualize the metastases.

2.2.8 Datasets and Analysis of Patient Samples
Level 3 TCGA RNAseqV2 gene expression data was obtained from the TCGA Data
Portal in March 2015. SKCM TCGA mutational data was obtained from the USCS Xena
browser for calls generated at the Broad Institute Genome Sequencing Center using the
MutDect

method

in

April

2015

(genome

cancer.ucsc.edu/download/public/xena/TCGA/TCGA.SKCM.sampleMap/mutation_broa
d).
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Stromal and immune scores were defined for tumours by the ESTIMATE algorithm
(Estimation of STromal and Immune cells in MAlignant Tumour tissues using
Expression data) using tumour RNASeqV2 data and the ESTIMATE package in R
(Yoshihara, Shahmoradgoli et al. 2013). Pearson’s correlation coefficient was used to
calculate the association of specific genes to stromal signatures.
We conducted all analyses and visualizations in the RStudio programming environment
(v0.98.501). R/Bioconductor packages ggplot2, plyr, and ESTIMATE were used where
appropriate.

2.3

Results

2.3.1 Loss of CCN2 expression by B16(F10) murine melanoma cells
results in impaired invasion but not proliferation
Initial experiments were conducted using B16(F10) melanoma cells which were stably
transfected with either CCN2 shRNA or scrambled control shRNA. Extent of CCN2
knockdown relative to GAPDH control was determined by real time PCR and Western
blot analyses (Figure 1A). To assess the invasive ability of the resultant melanoma cells,
B16(F10) cells were subjected a transwell filter invasion assay. After incubation at 37°C
for 24 hours, collagen and non-invasive cells were removed from the inside of the
transwell insert, and the number of remaining cells was calculated. B16(F10) melanoma
cells deficient in CCN2 showed markedly reduced invasion of collagen type I compared
with either wild type B16(F10) melanoma cells or control B16(F10) melanoma cells
stably transfected with scrambled control shRNA (Figure 1B, C). In order to ensure the
loss of invasive ability with CCN2 deficiency was also present in human melanomas, the
transwell filter invasion assay was also used to test C8161 and C81-61 cells. Both C8161
and its poorly aggressive counterpart were derived from metastases from the abdominal
wall, and mRNA and protein analysis revealed that C81-61 expressed significantly less
CCN2 (Seftor, Brown et al. 2005) (Figure 2A). Using siRNA transfection the CCN2
expression in C8161 cells was reduced (Figure 2A). Both the C8161 CCN2 siRNA cells,
and the C81-61 cells showed markedly reduced invasion as compared to control C8161
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Figure 2-1 Loss of CCN2 impairs the invasive ability of melanoma cells in vitro.
B16(F10) murine melanoma cells were transfected with either Ccn2 shRNA, to produce a
knockdown in Ccn2 mRNA expression, or a scrambled shRNA, to act as a control. (a)
Cells treated with the Ccn2 shRNA lentiviral particles showed a significant decrease in
Ccn2 mRNA expression compared to both untreated B16(F10) cells, and cells treated
with the scrambled control shRNA. (n=3, ** = p < 0.005) and a decrease in CCN2
protein present in growth media (b) Each cell line was subjected to a Boyden chamber
assay to assess their ability to invade through a collagen matrix. After being given 24
hours to invade through the collagen towards a chemotactic incentive the non-invasive
cells and collagen were removed and the invasive cells were stained with DAPI. (c) Cells
deficient in CCN2 were significantly less invasive than both untreated B16(F10) cells,
and cells treated with the scrambled control shRNA. (n = 3, *= p<0.05, **= p<0.01)
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Figure 2-2 CCN2 deficiency impairs invasive ability in human C8161 cells
C8161 cells were transfected with CCN2 siRNA, to produce a knockdown in CCN2
expression, or scrambled siRNA, to act as a control. (a, b) CCN2 siRNA transfected
C8161 cells, and poorly aggressive C81-61 show a significant decrease in CCN2 mRNA
and protein expression when compared to cells treated with scrambled control siRNA.
(c) Control siRNA transfected C8161 cells, CCN2 siRNA transfected C8161 cells, and
C81-61 cells were subjected to a Boyden chamber assay to assess their invasive ability.
After being given 24 hours to invade towards a chemotactic incentive, non-invasive cells
were removed and invasive cells were stained with DAPI. CCN2 siRNA transfected
C8161 cells and C81-61 cells showed significantly decreased invasion compared to
C8161 cells transfected with scrambled control siRNA (n = 4, ** = p<0.01, **** =
p<0.0001)
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cells (Figure 2 B, C). Of note, the reduced invasion observed with the loss of CCN2 was
not due to alterations in proliferation (Supplemental Figure 1A).

2.3.2 Loss of CCN2 expression by tumour stroma results in impaired
metastasis, but not tumour growth, in vivo
To extend our in vitro data supporting a role for CCN2 in melanoma invasion, we next
ascertained the in vivo effects of CCN2 loss on melanoma growth and invasion. To
perform these analyses, we employed a syngeneic model using B16(F10) melanoma cells
(which are derived from C57/BL6 mice) deleted or not for CCN2 and C57/BL6 mice
deleted or not for CCN2 in fibroblasts. Three weeks post-deletion of CCN2, we
subcutaneously injected mice with B16(F10) melanoma cells or B16(F10) melanoma
cells deleted for CCN2. Fourteen days later, tumour growth and metastasis were
examined. Growth of subcutaneous tumours over 14 days was unaffected by loss of
CCN2 expression (Supplemental Figure 1B), consistent with our in vitro data suggesting
that proliferation of melanoma cells was unaffected by loss of CCN2 (Supplemental
Figure 1A). When melanoma cells were injected into wild-type mice, loss of CCN2 in
melanoma cells did not significantly affect metastasis to the lung, measured using H&E
stained sections. Indeed, loss of CCN2 expression from stromal cells resulted in
increased metastasis in wild-type mice, likely due to a compensatory effect of stromal
CCN2 (Figure 3B). However, loss of CCN2 expression by tumour stroma resulted in
significant reduction in metastasis, regardless of whether CCN2 was knockdown in the
melanoma cells (Figure 3A, B). Loss of CCN2 from the tumour stroma of C57 BL6 mice
deleted for CCN2 after 14 days of tumour growth was confirmed by
immunohistochemical analysis using anti-CCN2 antibody (Figure 4A). Results indicating
that loss of CCN2 by tumour stroma resulted in impaired metastasis were confirmed by
gross examination of Bouin`s-fixed lungs of mice deleted or not for CCN2 after 21 days
of tumour growth (Figure 3C, D). Collectively, these results indicate that CCN2
expression by the tumour stroma could compensate for loss of CCN2 by tumour cells and
that CCN2 expression by the tumour stroma is required for metastasis in vivo.

47

48

Figure 2-3 Loss of CCN2 in tumour stroma fibroblasts impairs metastasis in vivo.
(a) Representative images of lung sections from wild type or Ccn2 Knockout mice (mice
deleted for CCN2 in fibroblasts) following subcutaneous implantation with Parental or
CCN2 shRNA melanoma cells after 14 days of tumour growth. H&E staining detects
sites of pulmonary metastasis by staining the dense metastatic foci purple (indicated by
arrow). (b) The graph quantifies the total area of the lung section covered by metastases.
Deletion of CCN2 in fibroblasts of the recipient mice results in a significant decrease in
metastasis compared to cells implanted into wild type mice (N = 8, * = P < 0.05). (c)
Images of lungs fixed with Bouin’s 21 days after tumour growth of parental melanoma
cells into wild type or Ccn2 Knockout mice. Note dark areas (indicated by an arrow),
indicating metastasized tumours, in wild type but not in (d) Ccn2 Knockout mice (mice
deleted for CCN2 in fibroblasts). N=3, representative images are shown.
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Figure 2-4 Loss of CCN2 and periostin expression in tumour stroma in mice deleted
for CCN2 in fibroblasts.
Sections of tumour stroma from wild type or Ccn2 Knockout mice (mice deleted for
CCN2 in fibroblasts) stained with (a) anti-CCN2 or (b) anti-periostin antibody (N=3,
representative images are shown). Mice were examined after 14 days of tumour growth
of parental melanoma cells or melanoma cells deleted for CCN2. Note that CCN2
appeared be localized to the cells (red arrow) whereas periostin appeared to be localized
to the matrix.
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2.3.3 Impaired invasive ability of CCN2-deficient B16(F10) melanoma
cells is rescued by recombinant periostin
To begin to address the underlying mechanism of CCN2-dependent action, we performed
genome-wide expression profiling of B16(F10) melanoma cells stably transfected with
CCN2 shRNA and scrambled control shRNA. We found that expression of 115 mRNA
were reduced greater than 1.5-fold in CCN2 shRNA-transfected B16(F10) melanoma
cells (Supplemental file). Of these, we noted that expression of perostin, a matricellular
protein previously implicated in cell migration, depended on CCN2 (Hamilton 2008).
Thus, we selected periostin for further analysis. Genome-wide expression profiling
analysis showing that periostin expression depended on CCN2 was confirmed by real
time PCR and Western blot analysis (Figure 5A). Addition of recombinant periostin
rescued the invasive defect of CCN2-deficient cells (Figure 5B,C). Loss of periostin from
the tumour stroma of C57/BL6 mice deleted for CCN2 after 14 days of tumour growth
was confirmed by immunohistochemical analysis using anti-periostin antibody (Figure
4B). These results suggest that the lack of invasive ability of CCN2-deficient melanoma
cells is due to lack of periostin expression.

2.3.4 In human melanoma patient samples, CCN2 and POSTN
expression are correlated with stromal content, and each
other
To investigate the role of CCN2 and POSTN in human melanoma samples, we looked at
the expression levels of both genes in 104 primary and 368 metastatic melanoma patient
samples from The Cancer Genome Atlas (TCGA). Stromal scores were calculated for
each sample by use of the ESTIMATE algorithm and correlated with CCN2 and POSTN
expression as determined by RNA sequencing. We found that both CCN2 and POSTN
correlated strongly with stromal scores (r=0.57 and 0.49, respectively), comparable to the
strength of the correlation between stromal scores and expression of fibroblast activation
protein (r=0.57), the quintessential tumour-associated stromal protein (Figure 6,
Supplemental Figure 2). We also found that CCN2 and POSTN expression positively
correlated with each other (r=0.33), providing support for a relationship between CCN2
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Figure 2-5 Rescuing Periostin deficiency rescues impaired invasion phenotype.
B16(F10) melanoma cells were transfected with either Ccn2 shRNA, to produce a
knockdown in Ccn2 mRNA expression, or a scrambled shRNA, to act as a control. (a)
Cells treated with the Ccn2 shRNA showed a significant decrease in Postn mRNA and
protein expression compared to cells treated with scrambled control shRNA. (b) Cells
treated with Ccn2 shRNA were treated with 150ng/mL rPOSTN and subjected to a
Boyden chamber assay to assess their ability to invade through a collagen matrix. After
being given 24 hours to invade through the collagen towards a chemotactic incentive the
non-invasive cells and collagen were removed and the invasive cells were stained with
DAPI. (c) Cells treated with 150ng/mL rPOSTN showed a rescue of the impaired
invasion phenotype displayed by Ccn2 shRNA treated cells (n = 3, **= p<0.01)
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Figure 2-6 CCN2 and POSTN expression correlate with stromal content
Stromal scores for primary (n=104) and metastatic (n=368) melanoma patient samples
from The Cancer Genome Atlas (TCGA) were calculated by use of the ESTIMATE
method. Stromal scores were analyzed for correlation with (a) CCN2 and (b) POSTN
gene expression values (log10(RSEM normalized count)) as determined by RNA
sequencing (Illumina HiSeq 2000 RNA Sequencing Version 2 analysis). Both CCN2 and
POSTN were found to highly correlate with the stromal scores (r=0.57 and 0.49,
respectively). (c) Scatterplot comparison of CCN2 and POSTN gene expression values
(log10(RSEM normalized count)) revealed a correlation between the expression of those
two genes in patient samples (r=0.33). Rug plots show the density of the data for given
values.
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and POSTN that extends to human melanoma patient samples (Figure 6). Intriguingly,
CCN2 (Supplemental Figure 3 A, B) and POSTN (Supplemental Figure 3 C, D)
expression did not correlate with the presence of B-RAF mutations in melanoma patients.
Conversely, CCN expression correlated with the activation state of protein kinase C in
human melanomas, and protein kinase C inhibition reduced CCN2 mRNA expression in
human and mouse melanoma cells (Supplemental Figure 4 A, B).
Collectively, these data confirm our in vitro and animal studies, and suggest that CCN2
and POSTN are highly stromally expressed and that these matricellular proteins are coregulated.

2.4

Discussion

Our results demonstrated that CCN2 expression by tumour stroma is required for
melanoma metastasis. An emerging concept is that alterations in the tumour
microenvironment promote invasion and metastasis and thus that targeting these
alterations may result in effective anti-cancer therapies (Jewer, Findlay et al. 2012, Quail,
Taylor et al. 2012). Matricellular proteins such as CCN2 and periostin are secreted into
the extracellular matrix (ECM) that are highly spatiotemporally regulated and, although
they are not structural ECM components, alter adhesive signaling in response to ECM
and growth factors and hence can have profound localized effects on cellular behavior.
The CCN family of matricellular proteins, at least in part due to its ability to promote
signaling via integrins, has recently been proposed to play significant roles in altering the
tumour microenvironment hence contributing to tumour growth and metastasis. Previous
studies have found that CCN2 is abundant in cancers such as pancreatic cancer, and that
this overexpression is related to cancer progression (Aikawa, Gunn et al. 2006,
Dornhofer, Spong et al. 2006, Kondo, Kubota et al. 2006, Bennewith, Huang et al. 2009,
Sodek, Ringuette et al. 2009, Mao, Ma et al. 2011). Our results showing that fibroblastderived CCN2 contributes to melanoma metastasis suggest that CCN2 may be a good
target for drug intervention in melanoma. Our data are consistent with and extend
previous data showing that CCN2 is upregulated in cancer cells in response to hypoxia,
oncogenic ras, and YAP/TAZ/hippo and that an antibody against CCN2 blocks
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progression in animal models of pancreatic cancer and melanoma (Aikawa, Gunn et al.
2006, Sha and Leask 2011, Finger, Cheng et al. 2014, Nallet-Staub, Marsaud et al. 2014)
Periostin, like CCN2, is a matricellular protein upregulated in conditions wherein the
ECM is being remodeled (Hamilton 2008). Our data suggesting that periostin operates
downstream of CCN2 to promote invasion is consistent with prior data using periodontal
ligament cells that showed rCCN2 induced periostin expression (Asano, Kubota et al.
2005); however, our data is the first to link CCN2 and periostin in terms of tumour
metastasis. In this regard, it is interesting to note that CCN2 appeared to be largely
localized to the cell, whereas periostin appeared to be present in the ECM. Previous data
has linked periostin expression with metastasis in some tumours including in invasive
melanoma (Tilman, Mattiussi et al. 2007, Kotobuki, Yang et al. 2014). Moreover,
periostin has been shown to be upregulated in fibroblasts in the tumour
microenvironment (Kikuchi, Kunita et al. 2014) and studies indicate that it promotes the
invasiveness of pancreatic tumour cells (Baril, Gangeswaran et al. 2007). However, this
is the first report to link tumour invasion in melanoma with periostin expression,
consistent with the notion that targeting periostin may prove to be a viable anti-cancer
therapy.
40–60% of all cutaneous melanoma patients possess position 600 mutations in BRAF; in
these patients, tumours shrink in response to the BRAF inhibitors vemurafenib and
dabrafenib (Fedorenko, Gibney et al. 2015). However, patients develop resistance to
these drugs (Fedorenko, Gibney et al. 2015). That neither periostin nor CCN2 expression
correlate with BRAF mutations suggest that anti-periostin or anti-CCN2 therapies may
represent novel therapeutic strategies with an entirely different mechanism of action. As
CCN2 expression appears to be downstream of PKC, possibly CCN2 elicits its effects by
mediating combined protein kinase C/MAP kinase or protein kinase C/Akt pathways
(Musi, Ambrosini et al. 2014).
In summation, herein we have provided data that suggest that CCN2 present in the
tumour stroma is required for melanoma metastasis. These data are consistent with the
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hypothesis that blocking CCN2 action may be a novel approach to mitigate progression
of melanoma.
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Supplemental Figure 1: Loss of CCN2 does not affect the proliferation of melanoma
cells.
(a) B16(F10) murine melanoma cells were transfected with either CCN2 shRNA, to
produce a knockdown in Ccn2 mRNA expression, or a scrambled shRNA, to act as a
control. Proliferation of the cells was then determined by measuring the rate of BrdU
incorporation into newly synthesized DNA after for 6 or 24 hours.

There was no

significant difference in the rates of BrdU incorporation between cells, indicating that
DNA was synthesized at the same rate, and thus cell proliferation was unaffected (n = 3).
(b) Parental or CCN2 shRNA B16(F10) melanoma cells were implanted subcutaneously
into mice whose fibroblasts were either CCN2 competent or deficient, and allowed to
grow for 14 days. Neither reduced CCN2 expression in the tumour cells nor the stroma
altered tumour growth.

Kruskal-Wallis analysis shows no significant difference in

growth at any time point. (N = 8)
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Supplemental Figure 2. Correlation of HMGA2 and FAP to stromal content.
Stromal scores for primary (n=104) and metastatic (n=368) melanoma patient samples
from The Cancer Genome Atlas (TCGA) were calculated by use of the ESTIMATE
method. Stromal scores were analyzed for correlation with (a) HMGA2 and (b) FAP gene
expression values (log10(RSEM normalized count)) as determined by RNA sequencing
(Illumina HiSeq 2000 RNA Sequencing Version 2 analysis). FAP was found to highly
correlate with the stromal scores (r=0.57). Rug plots show the density of the data for
given values.
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Supplemental Figure 3. CCN2 and POSTN expression do not correlate with B-RAF
mutation
Barplots show no significant difference in the expression levels of (a, b) CCN2 and (c,d)
POSTN in (a,c) BRAF mutated or (b,d) BRAFV600 mutated human melanoma tumour
samples from The Cancer Genome Atlas. (mean+/-SEM, n=296, significance determined
by t test)
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Supplemental Figure 4. CCN2 Expression is elevated in a PKC dependent fashion.
a) Scatterplot displaying the positive correlation between CCN2 expression values
(RNA-sequencing, log(RSEM normalized count)) and PKC alpha pS657 protein levels
(RPPA) in TCGA melanoma patient samples. Rug plots show the density of the data for
given values. Pearson correlation coefficient = 0.29, p<0.01. (b) Treatment with 10µM
Bisindolylmaleimide I (BIM) showed a significant reduction in CCN2 mRNA expression
in both B16F10 and C8161 cells (n = 3, **** = p<0.001)
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Chapter 3

3

CCN2 expression in tumour stroma is required for
tumour vascularization and formation of a contractile
stroma
3.1

Introduction

Melanoma is an invasive cancer that is increasing in frequency, and due to its metastatic
ability and resistance to therapies is highly fatal with only 5% of metastatic melanoma
patients expected to survive for 5 years after diagnosis (Cummins, Cummins et al. 2006,
Reed, Brewer et al. 2012). There has been a large amount of effort directed towards
finding therapies to improve patient outcomes in melanoma, but these efforts have
yielded limited results so far. Although initially regarded as promising breakthroughs,
small molecule inhibitors targetting the BRAF mutation show limited windows of
efficacy before the tumour rapidly adapts, with almost all patients acquiring resistance to
the therapy (Lim, Menzies et al. 2017). One theory as to what causes this resistance and
subsequent tumour resurgence is that inhibition of growth and survival signals by BRAF
inhibitors can be overcome by activation of alternate signaling pathways driven by β1
integrin-mediated pro-adhesive associations with the extracellular matrix (Hirata, Girotti
et al. 2015).
Another promising area of investigation is in disrupting the vascular networks feeding
tumours, since avascular tumours are limited in size by the distance that oxygen can
diffuse through tissue to reach the core of the tumour (Zaki, Basu et al. 2012, Maj,
Papiernik et al. 2016). In addition to allowing for the delivery of oxygen and the removal
of metabolic waste products from proliferating cancer cells, the vasculature of a tumour
provides easy access to the circulatory system of the body, and thus is a potential
pathway for metastasis (van Zijl, Krupitza et al. 2011). While there are many different
strategies and specific targets, the majority of anti-angiogenic therapies developed to date
have focused on disruption of the VEGF signaling pathway (Maj, Papiernik et al. 2016)
Despite some promising preclinical results, these therapies have also been largely
ineffective in melanoma due to the upregulation of non-VEGF derived vascularization
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mechanisms within the tumour and associated stroma. These can include activation of
alternate pathways for inducing endothelial cell based angiogenesis, co-option of
endogenous vascular networks, and a process called Vasculogenic Mimicry involving the
acquisition of endothelial-like phenotypes by melanoma cells allowing them to form
vascular networks independent of endothelial cell angiogenesis (Bergers and Hanahan
2008, Pastushenko, Vermeulen et al. 2014, Felcht and Thomas 2015).
While VEGF is the primary signaling pathway involved in sprouting angiogenesis, as
seen in development and wound healing, there are many other molecules within the
extracellular matrix that are integrally involved in the process of tumour vascularization
as well: Matrix metalloproteinases are involved in degrading extracellular matrix and
liberating bound pro-angiogenic factors, Transforming Growth Factor β is involved in the
recruitment of perivascular cells which stabilize newly formed vasculature, and several
different collagens promote angiogenesis through integrin signaling (Pastushenko,
Vermeulen et al. 2014, Felcht and Thomas 2015, Mongiat, Andreuzzi et al. 2016). The
CCN family of matricellular proteins serve as regulators and modulators of how cells
interact with their environment by mediating signaling of growth factors, extracellular
matrix components, and other cytokines to cell surface receptors (Leask and Abraham
2006, Mongiat, Andreuzzi et al. 2016). CCN2 (formerly known as CTGF) is expressed
by activated fibroblasts like those found in the tumour stroma, and is involved in
angiogenesis by promoting pericyte recruitment and basement membrane organization; in
fact, CCN2 null mice exhibit severe vascular defects and die shortly after birth (Mongiat,
Andreuzzi et al. 2016).
In this report we use a syngeneic model of C57 BL6 mice with a conditional CCN2
deletion in fibroblasts and B16F(10) murine melanoma cells to investigate the role of
stromal CCN2 in the activation of a contractile, α-SMA expressing stroma and tumour
vascularization.
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3.2

Methods

3.2.1 Cell Culture
B16(F10) murine melanoma cells were purchased (ATCC) and cultured in high glucose
Dulbecco's Modified Eagle's Medium (DMEM), 10% fetal bovine serum (FBS) and 1%
antibiotic/antimycotic solution (Invitrogen). When indicated, cells were transfected with
CTGF (CCN2) shRNA Lentiviral or control shRNA Lentiviral Particles (Santa Cruz)
using polybrene and selected for using puromycin as described by the manufacturer
(Santa Cruz).

3.2.2 In vivo tubule formation assay
50μL of Geltrex LDEV-free reduced growth factor basement membrane matrix (Thermo
Fisher Scientific) was added to each well of a 96-well plate, and incubated at 37°C to
allow polymerization. 10,000 cells were seeded in serum-free DMEM and incubated for
8 hours. Formed tubules were imaged on Carl Zeiss Imager M2m microscope (Carl
Zeiss, Jena, Germany) using Zen Pro 2012 software. Tubule area and number of tubules
and nodes were quantified using ImageJ 1.48v (National Institutes of Health, Bethesda,
MD, USA).

3.2.3 Conditioned Media (CM) sample preparation
To prepare CM for LC-MS/MS, ~20 mL of CM was concentrated using a Amicon Ultra15 3kDa MWCO ultracentrifugal units spun at 3000x g at 4C for 1.5 hours in a swinging
bucket rotor. CM was subsequent rinsed with PBS to remove excess dye. Concentrated
CM was lyophilized overnight and then dissolved in 8M Urea, 50mM ammonium
bicarbonate (ABC), 10mM dithiothreitol (DTT), 2% SDS lysis buffer the following day.
CM was quantifed using a Pierce™ 660nm Protein Assay (ThermoFisher Scientific) with
ionic detegent compatibility reagent (ThermoFisher Scientific) and ~25ug of CM proteins
were reduced in 10mM DTT for 30 minutes and alkylated in 100mM iodoacetamide
(IAA) for 30 minutes at room temperature in the dark. CM proteins were subsequently
precipitated in chloroform/methanol in 1.5mL microfuge tubes according to Wessel and
Flügge (Wessel and Flugge 1984). Briefly, CM samples were topped up to 150µL with
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50mM ABC, mixed with 600μL of -20°C methanol followed by 150μL of -20°C
chloroform and vortexed thoroughly. An additional volume of 450μL of 4°C water was
added before additional vortexing and centrifugation at 14, 000 xg for 5 min. The upper
aqueous/methanol phase was carefully removed to avoid disturbing the precipitated
protein interphase. A second 450μL volume of cold methanol was added to each sample
followed by vigorous vortexing and centrifugation at 14, 000 xg for 5 min. The remaining
chloroform/methanol was discarded and the precipitated protein pellet was left to air dry
in a fume hood.

3.2.4 CM protein digestion
On-pellet protein digestion was performed similarly to Duan et al.(Duan, Young et al.
2009). Briefly, 100µL of 50mM ABC (pH 8) plus LysC/Trypsin (Promega) (1:50 ratio)
was added to precipitated CM proteins and vortexed vigorously. CM samples were
incubated at 37°C overnight (~18h) in a water bath shaker (Polyscience) at 190 rpm. An
additional volume of trypsin (Promega)(1:100 ratio) was added the next day for ~4 hours
before acidifying to pH 3-4 with 10% fumaric acid (FA). CM digests were centrifuged at
14,000 xg to pellet insoluble material before SCX peptide fractionation.

3.2.5 SCX peptide fractionation
Tryptic peptides recovered from CM digests were fractionated using SCX StageTips
similarly to Kulak et al.(Kulak, Pichler et al. 2014). Briefly, peptides were acidified with
1% trifluoroacetic acid (TFA) and loaded onto a pre-rinsed 12-plug SCX StageTips. In
total total, 7 SCX fractions were collected by eluting in 50,75, 125, 200, 250, 300 mM
ammonium acetate/20% ACN followed by a final elution in 5 mM ammonium
hydroxide/80% acetonitrile (ACN). SCX fractions were dried in a SpeedVac (Thermo
Fisher), resuspended in ddH2O, and dried again to evaporate residual ammonium acetate.
All samples were resuspended in 0.1% FA prior to LC-MS/MS analysis.

3.2.6 LC-MS/MS
SCX fractions were analyzed using an nanoAquity UPLC system (Waters) connected to a
Orbitrap Elite mass spectrometer (Thermo Scientific). Buffer A consisted of water/0.1%
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FA and Buffer B consisted of ACN/0.1%FA. Peptides (~1µg estimated by BCA) were
initially loaded onto an ACQUITY UPLC C18 Trap Column, 5 µm, 180 µm x 20 mm
and trapped for 5 minutes at a flow rate of 10 µl/min at 99% A/1% B. Peptides were
separated on an ACQUITY UPLC Peptide BEH C18 Column, 130Å, 1.7µm, 75µm x
250mm operating at a flow rate of 300 nL/min at 35°C using a non-linear gradient
starting at 5% B then 7.5% B over 1 minute, 7-25% B over 179 minutes and 25-32.5% B
over 30 minutes before increasing to 95% B and washing. MS precursor scans were
acquired in the Orbitrap at a resolution of 60K (m/z window of 400-1450). MS/MS was
performed on the top 20 most intense precursor ions in linear ion trap operating in rapid
CID mode (isolation width of 2.0 m/z). A dynamic exclusion width of 30 seconds was
used (dynamic exclusion mass width low and high were set to 0.5 and 1.5 respectively).
An AGC target of 10000 and maximum injection time of 50 ms was used for MS/MS in
the ion trap. A minimum signal threshold of 1000 and normalized collision energy of
35% was used for fragmentation. The lock mass was 445.120025 for ppm correction.

3.2.7 Data Analysis
All raw MS raw files were searched in MaxQuant (1.5.2.8) using the Mouse Uniprot
database (reviewed only; updated Dec 2015). Missed cleavages were set to 3 and I=L.
Cysteine carbamidomethylation was set as a fixed modification. Oxidation (M), Nterminal Acetylation (protein), and Deamidation (NQ) were set as a variable
modifications (max. number of modifications per peptide = 5) and all other setting were
left as default. Precursor mass deviation was left at 20 ppm and 4.5 ppm for first and
main search, respectively. Fragment mass deviation was left at 20 ppm. Protein and
peptide FDR was set to 0.01 (1%) and the decoy database was set to revert. Datasets were
loaded into Perseus (1.5.2.6) and proteins identified by site, reverse and potential
contaminants were removed. LFQ intensities were log2 transformed and missing values
were imputed using a width of 0.3 and down shift of 1.8.

3.2.8 ELISA
Secreted VEGFa and proCOL1a1 levels were determined in triplicate using a Quantikine
Mouse VEGF ELISA kit (R&D Systems) and Mouse Pro-Collagen I alpha 1 ELISA kit
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(Abcam). Assays were performed according to the manufacturer's instructions, with 5
times dilution of conditioned media for VEGF assay. A standard curve was constructed
for each assay (linear between 31.3 and 2000 pg/mL for ProCOL1a1 and between 7.8 and
500 pg/mL for VEGF).

3.2.9 Animals
Mice possessing a tamoxifen-dependent Cre recombinase under the control of a
fibroblast-specific regulatory sequence from the proα2(I) collagen gene (Zheng, Zhang et
al. 2002) were crossed with mice homozygous for a conditional CCN2 allele to generate
Cre/CCN2 heterozygote mice, which were mated to generate mice hemizygous for Cre
and homozygous for CCN2. For immunohistochemistry experiments these mice were
mated with Col1a2-Cre(ER)T;Rosa26mTmG mice, generated as previously described
(Liu and Leask 2013), resulting in Cre/CCN2/mTmG heterozygote mice which were
mated to generate mice hemizygous for Cre and homozygous for CCN2 and mTmG.
Animals used for experiments were genotyped by polymerase chain reaction (PCR) as
described previously (Zheng, Zhang et al. 2002, Liu, Shi-wen et al. 2011). To delete
CCN2 (CCN2-/-), excise tdTomato, and trigger expression of GFP in fibroblasts, 3-weekold mice were given intraperitoneal injections of tamoxifen suspension (0.1 ml of 10
mg/mL 4-hydroxitamoxifen, Sigma) over 5 days. Col1a2-Cre(ER)T;Rosa26mTmG were
also injected with tamoxifen, and were used as controls (CCN2fl/fl). For micro-CT
experiments 3-week-old Cre/CCN2 mice were given intraperitoneal injections of
tamoxifen suspension over 5 days to delete CCN2 (CCN2-/-), and littermate contols
injected with corn oil were used as controls (CCN2fl/fl). All animal protocols were
approved by the animal care committee at the University of Western Ontario.

3.2.10

In vivo tumour implantation

Subconfluent melanoma cells in the exponential growth phase were harvested by
exposure to 0.25% trypsin/0.02% EDTA solution, resuspended in serum-free DMEM at a
concentration of 3300 cells/µL, and 330,000 cells were injected subcutaneously into the
right flank of each mouse. After appearance of a palpable tumour mice were monitored
for 14 days before being euthanized. After euthanasia mice were either perfused with
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micro-CT contrast agent as described below, or tumours were harvested, embedded in
TissueTek O.C.T. compound (VWR), and frozen.

3.2.11

Immunohistochemistry

Frozen sections (20μm) were cut at -22°C using a refrigerated microtome Leica CM1900
UV cryostat (Leica, Concord, ON, Canada) and collected on Superfrost Plus slides
(Fisher Scientific, Ottawa, ON, Canada). Excess O.C.T. compound was removed from
sections by soaking in PBS for 30 minutes prior to blocking with 10% serum in 0.1%
Triton X-100 in PBS for 1 hour and then in primary antibody in 10% serum in 0.1%
Triton X-100 in PBS overnight in a humidified chamber at 4°C overnight. The primary
antibodies used in this study were: anti-α-SMA (1:2000 dilution; Sigma), anti-vWF
(1:200 dilution; Chemicon International), anti-SOX2 conjugated to Alexa Fluor 647
(1:100 dilution; abcam). After primary antibody incubation sections were rinsed and
incubated in appropriate secondary antibodies (Jackson ImmunoResearch) at room
temperature (~23°C) for 1 hour. Sections were rinsed, mounted and imaged on a Zeiss
fluorescence microscope and Northern Eclipse software.

3.2.12

Vascular perfusion of micro-CT contrast agent

Mice were injected intraperitoneally with sodium heparin solution to prevent coagulation.
After 15 minutes the mice were euthanized by isofluorane asphyxiation to preserve
vascular structure. Each mouse had its chest opened to reveal the heart. A small incision
was made in the right atrium to allow for drainage of blood, and a butterfly needle was
inserted into the left ventricle. Heparinized saline was run through the butterfly needle at
~120 mmHg to flush the vasculature of blood. Once the vasculature was cleared of blood
Microfil (Flow-Tech, Carver, MA) was run through the butterfly needle until vasculature
was fully perfused. Microfil was allowed to polymerize for approximately 30 minutes
before the butterfly needle was removed and the mouse was immersed in 4% PFA until
fixed (approximately 24 hours). After preliminary CT scans to ensure full vascular
perfusion of each mouse, tumours were removed and embedded in paraffin for high
resolution X-ray micro-CT acquisition.
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3.2.13

X-ray micro-CT acquisition

Samples were scanned on a GE Locus MS-8 x-ray conebeam micro-CT imaging system
(GE Medical Systems, London, ON) operating at a peak energy of 80 kVp and tube
current of 80 μA. 900 X-ray projections were acquired at 0.4 degree angular increments
during a full 360 degree rotation of the sample. Each projection was the average of 4
frames with an integration time of 3000 ms. The data was reconstructed into a 3D data
set with isotropic 11.473 μm voxel spacing using custom software employing a Feldkamp
filtered-backprojection algorithm. Water-filled compartments and air regions were
included in each scan as an internal reference in order to ensure that the final
reconstructions were properly calibrated in Hounsfield Units (HU). Visualization and
analysis of the 3D μCT data was performed in MicroView (GE Healthcare, Parallax
Innovations, London, ON).

3.2.14

Datasets and Analysis of Patient Samples

Level 3 TCGA RNAseqV2 gene expression data was obtained from the TCGA Data
Portal in January 2016. Enrichment for CCN2 associated gene sets was conducted using
Generally Applicable Gene-set Enrichment (GAGE, v2.12.3). Hallmark gene sets were
downloaded from the Molecular Signatures Database
(http://software.broadinstitute.org/gsea/msigdb) v5.0 on 10 August 2015 (Subramanian,
Tamayo et al. 2005). Enrichment was calculated against a formulated sample composed
of the mean expression values for each gene and sample-specific test statistics were
correlated to CCN2 expression values (log10[RSEM+1]) using Spearman’s rank
correlation. The heatmap was constructed using genes from the Hallmark Angiogenesis
gene set that correlated with CCN2 expression values (log10[RSEM+1]) with a rho>0.25.
We conducted all analyses and visualizations in the RStudio programming environment
(v0.98.501). R/Bioconductor packages ggplot2, plyr, gplots, and GAGE were used where
appropriate.
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3.3

Results

3.3.1 CCN2 in fibroblasts is required for the activation of contractile
stroma
B16F(10) melanoma cells were injected subcutaneously into syngeneic C57 BL6 mice
deleted for CCN2 or not in fibroblasts, and expressing GFP in fibroblasts. Melanoma
cells were injected 2 weeks after gene deletion, and were allowed to grow for 14 days
after the detection of a palpable tumour. Fresh tumour tissue was harvested and frozen in
O.C.T. for sectioning. Sections were stained for anti-αSMA to determine the extent to
which the stroma had adopted a contractile phenotype, and anti-SOX2 as myofibroblasts
in fibrotic environments have been shown to largely express SOX2 (Tsang and Leask
2015) (Figure 1). While there was no difference in the proportion of stromal cells
derived from fibroblasts (GFP positive cells), there was a significant reduction in the
proportion of cells expressing SOX2 and almost no cells expressing αSMA in mice
deleted for CCN2 in the stroma compared to wild-type. Additionally, the proportion of
cells co-expressing GFP and SOX2 was also reduced.
These results indicate that CCN2 is not required for the recruitment of fibroblasts to the
tumour stroma, but it is required for those fibroblasts to acquire SOX2 and αSMA
expression, and also for non-fibroblast derived cells to acquire their expression.

3.3.2 Loss of CCN2 expression in the stroma resulted in impaired
tumour vascularization in vivo
As lack of CCN2 causes perinatal death due to inadequate basement membrane formation
and lack of pericyte recruitment to vasculature we investigated the effects of CCN2 on
tumour vascularization. B16F(10) melanoma cells were injected subcutaneously into
syngeneic C57 BL6 mice deleted for CCN2 in fibroblasts or not. After growing for 14
days after the appearance of a palpable tumour the mice were perfused with a micro-CT
contrast agent, tumours were harvested and then scanned by x-ray micro-CT. After being
calibrated against an air-water capsule, total volume of tumour and total volume of
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Figure 3-1 Loss of CCN2 prevents activation of αSMA and expression of plasticity
marker SOX2
Sections of tumour stroma from wild-type or Ccn2-knockout mice (mice deleted for
CCN2 in fibroblasts) which contain a GFP reporter for cells expressing collagen 1α2
(synthetic fibroblasts) at 3 weeks of age. (a) Sections were stained for αSMA (blue),
SOX2 (violet), and GFP (green). Ccn2-knockout mice showed a significant reduction in
(b) the number of cells of fibroblastic origin (GFP positive), (c) stromal SOX2 and (d)
αSMA expression, as well as a significant reduction in the number of cells co-expressing
GFP with (e) SOX2 and (f) αSMA (t-test, n = 3, * = p<0.05, *** = p<0.001, **** =
p<0.0001)
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tumour vasculature were calculated. Tumours in mice with CCN2 deleted in fibroblasts
had significantly less vascular volume than those in wild-type mice (Figure 2). To see if
this extended into human melanoma patients we looked at mRNA expression levels of
470 melanoma patient samples from The Cancer Genome Atlas (TCGA). CCN2
expression was strongly correlated with expression of genes in the angiogenesis gene set
(Figure 3).
Taken together, this data indicates that stromal CCN2 expression is an important factor in
the vascularization of tumours.

3.3.3 Loss of CCN2 in melanoma cells reduces secreted proangiogenic proteins and impairs vasculogenic mimicry in
vitro and loss of CCN2 expression in the stroma impairs
vasculogenic mimicry in vivo.
In order to determine what aspects of tumour vascularization were being affected by the
loss of CCN2 we performed a matrigel tubule formation assay on B16F(10) melanoma
cells that have been stably transfected with CCN2 shRNA or scrambled control shRNA.
The cells transfected with CCN2 shRNA formed fewer tubules, which covered less area
and met at fewer nodes, indicating a less robust network (Figure 4). This assay is
typically used to determine the angiogenic potential of endothelial cells subjected to
various treatments, and so is a reflection of the ability of the melanoma cells to mimic an
endothelial cell phenotype by forming a tubule network. We also assessed the production
and secretion of pro-angiogenic proteins by these cells. As a hypothesis-generating
experiment we harvested conditioned media from the cells, concentrated the protein, and
analyzed it by mass spectrometry. Analysis of secreted proteins with altered expression
for functional groups revealed that pro-angiogenic proteins were reduced in the absence
of CCN2 (Figure 6A). ELISAs were performed to confirm that secreted VEGFa (the
major signaling ligand in angiogenesis) and proCOL1a1 (which increases angiogenic
signaling through integrins and is required for capillary lumen formation) were reduced
(Mongiat, Andreuzzi et al. 2016) (Figure 6B).
In order to determine the aspects of tumour vascularization being affected by loss of
stromal CCN2 we implanted B16F(10) cells into mice deleted for CCN2 or not in the
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Figure 3-2 Deletion of Stromal CCN2 Reduces Tumour Vasculature
Tumours in wild-type or Ccn2-knockout mice (mice deleted for CCN2 in fibroblasts)
were perfused with a CT-contrast agent (Microfil, Flow Tech Inc.) by injection through
left ventricle and imaged. Percent volume of tumour occupied by vasculature was
calculated. Mice lacking CCN2 in their fibroblasts had significantly reduced vascular
volume (t-test, n = 3, p < 0.05)
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Figure 3-3 CCN2 expression correlates with angiogenesis in clinical samples
Gene expression data for melanoma patient samples (n = 468) from The Cancer Genome
Atlas (TCGA) were analyzed for enrichment using the Generally Applicable Gene-set
Enrichment (Gage, v2.12.3). Sample expression of CCN2 was strongly correlated with
enrichment of genes in the Angiogenesis gene-set (Spearman’s p<2.2e-16). Analysis was
performed by Krista Vincent of the Postovit Lab at University of Alberta.
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Figure 3-4 Loss of CCN2 decreases the capacity of B16F10 cells to form tubules in
vitro
B16(F10) melanoma cells were transfected with either CCN2 short hairpin RNA
(shRNA), to produce a knockdown in Ccn2 mRNA expression, or a scrambled shRNA, to
act as a control. Cells were subjected to a tubule formation assay where 2000 cells/well
were seeded in serum-free DMEM in a 96-well plate pre-coated in matrigel. After 8
hours incubation (a) images at the center of each well were taken. Cells transfected with
CCN2 shRNA showed a significantly decreased (b) number of tubules formed, (c) total
area of tubules formed, and (d) number of nodes linking multiple tubules together (n = 7,
* = p<0.05, **** = p<0.0001)
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Figure 3-5 Loss of stromal CCN2 reduces tumour-derived vasculature in vivo
a) Sections of tumour stroma from wild-type or Ccn2-knockout mice (mice deleted for
CCN2 in fibroblasts) which contain a GFP reporter for cells expressing collagen 1α2
(synthetic fibroblasts) at the time of deletion (3 weeks of age). Sections were stained
with DAPI(blue), anti-vWF (white), tdTomato (red), and GFP (green). Ccn2-knockout
mice have (b) reduced tumour vasculature, and (c) a reduced proportion of tumour
vasculature derived from implanted tumour cells (n = 3, * = p<0.05, ** = p<0.01)
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Figure 3-6 CCN2 knockdown reduces expression of secreted proteins associated
with angiogenesis from B16(F10) cells
B16(F10) melanoma cells were transfected with either CCN2 short hairpin RNA
(shRNA), to produce a knockdown in Ccn2 mRNA expression, or a scrambled shRNA, to
act as a control. Cells were cultured in serum-free DMEM and conditioned media was
collected. a) Secreted protein was analyzed by mass spectrometry to determine
functional clusters affected by CCN2 deficiency (n = 1), and (b) ELISA to confirm
changes in secreted VEGF (R&D Systems, MMV00) and COL1A1 (abcam, ab210579)
(n = 3, * = p<0.05, **** = p<0.0001). Mass spectrometry performed by Dylan DietersCastator of Lajoie lab at University of Western Ontario.
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fibroblasts, and which express GFP in fibroblasts and TdTomato in other cell types.
Tumours were allowed to grow for 14 days after the appearance of a palpable tumour
before being stained for anti-vWF to detect active vasculature (Figure 5A). The
percentage of each section occupied by vasculature with blood flow at time of sacrifice
was measured (Figure 5B), and then the percentage of that vascular area which was
positive for either GFP or RFP, indicating that vessel was derived from host tissue, or
was negative for both GFP and RFP, indicating that the vessel was derived from tumour
cells, was calculated (Figure 5C). Tumours from mice with CCN2 deleted in fibroblasts
had significantly lower vascular area, and significantly less of their vasculature was
tumour derived.

3.4

Discussion

CCN2 in the tumour stroma has been shown to increase melanoma metastasis, but the
mechanism behind how it does so is unclear (Hutchenreuther, Vincent et al. 2015). Our
results in this report demonstrated that the loss of CCN2 from the fibroblasts of the
tumour stroma resulted in a decrease of vascular volume of the tumour. They also
demonstrate a reduced capability for the tumour stroma to acquire an activated, αSMA
expressing phenotype in response to tumour implantation.
Tumours implanted into mice deleted for CCN2 or not in fibroblasts showed a significant
reduction in stromal SOX2 expression (Fig. 3-1). SOX2 is a transcription factor that is
required for stem-cell maintenance, and two major cell types that express SOX2 in the
stroma are mesenchymal stromal cells and specific subpopulations of cancer associated
fibroblasts (Domenech 2017). Cancer associated fibroblasts expressing higher levels of
stem-markers like SOX2 belong to a subpopulation that exerts powerful promigratory
effects on tumour cells through paracrine signaling (Herrera, Islam et al. 2013). This
phenotype is also significantly associated with activation of αSMA expression in the
fibroblasts (Herrera, Islam et al. 2013). Multipotent mesenchymal stromal cells can
promote tumour vascularization by secreting factors that promote endothelial cell tubule
formation, or by providing cells to form perivascular muscular layers of blood vessels,
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and mesenchymal stromal cells expressing higher levels of SOX2 displayed an increased
ability to revascularize wounded tissues (Rustad, Wong et al. 2012, Domenech 2017)
CCN2 has been implicated in angiogenesis, as CCN2 null mice die perinatally due in part
to vascular defects such as poor basement membrane organization and lack of
pericytes/smooth muscle cells (Mongiat, Andreuzzi et al. 2016). Additionally, CCN2 can
induce VEGF expression through HIF-1α-dependent activation of PI3K, ERK, NF-κB
and recombinant CCN2 promotes angiogenesis in vivo when applied to corneas (Leask
and Abraham 2006, Mongiat, Andreuzzi et al. 2016). As such, we investigated the role
of stromal CCN2 on the vascularization of melanoma.
While there has been a great deal of interest in developing anti-angiogenic therapies,
most focus on VEGF and alternate pathways that can promote angiogenesis, or even
alternate methods of vascularization that do not require angiogenesis have led to therapy
failure (Maj, Papiernik et al. 2016). One of the mechanisms through which tumours can
evade VEGF targeted therapies is through the expression of endothelial cell markers and
the formation of vascular networks by the tumour cells themselves in a process called
vasculogenic mimicry. We demonstrated that in vitro B16F(10) murine melanoma cells
deleted for CCN2 showed a decreased capacity to form vasculogenic mimicry tubule
networks, and reduced secretion of pro-angiogenic proteins. Among the secreted proteins
reduced were VEGF, the major signaling ligand in sprouting angiogenesis, but also type I
collagen α1 which induces survival signaling in endothelial cells and is required for
proper capillary formation (Mongiat, Andreuzzi et al. 2016). By implanting tumours into
mice that endogenously express GFP or TdTomato reporters in host cells but not tumour
cells, and staining for vasculature we were demonstrated that the impaired vasculogenic
mimicry in vitro was also seen in vivo.
In summation, this report demonstrates that loss of stromal CCN2 decreases vascular
volume of tumours in vivo, that loss of CCN2 from melanoma cells decreases secretion of
pro-angiogenic proteins in vitro, and that it decreases vasculogenic mimicry both in vitro
and in vivo.
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Chapter 4

4

CCN1 Expression in tumour stroma is required for
collagen organization and melanoma metastasis
4.1

Introduction

Melanoma is an invasive cancer that is disproportionately found in young adults, and
with an increasing frequency (Reed, Brewer et al. 2012). The high metastatic rate of
melanoma makes it the most likely skin cancer to be fatal (Society 2013). Melanocytes
are routinely assaulted by ultraviolet radiation and are highly resistant to apoptosis.
Accordingly, melanoma is remarkably resistant to conventional anti-cancer treatments,
leaving surgical excision as the only viable treatment (Soengas and Lowe 2003).
Unfortunately, once metastasis has occurred surgical excision is no longer an effective
treatment option with 5 year survival rates dropping from 90% for patients with no
metastases to 36% in the presence of even local metastasis and 5% in the case of distant
metastases (Homsi, Kashani-Sabet et al. 2005, Cummins, Cummins et al. 2006).
In order for cells to metastasize they have to leave the primary tumour and migrate
through the activated stromal extracellular matrix. Activated cancer associated
fibroblasts (CAFs) produce, organize and remodel the extracellular matrix and
accordingly have significant effects on the rate and method of invasion. Stromal CAFs
secrete a variety of cytokines, including transforming growth factor (TGF) β, that
increase the adhesive and invasive abilities of cancer cells, and also remodel the
extracellular matrix to increase stiffness and realign collagen fibres to facilitate cancer
cell migration (Provenzano, Inman et al. 2008, Horimoto, Polanska et al. 2012, Kalluri
2016). Many of these pro-invasive processes are mediated by signaling and adhesion
through integrins (Steeg 2006, Margadant and Sonnenberg 2010).
Abnormal expression of the CCN (named for the three prototypical members Cyr61,
CTGF, and NOV) family of matricellular proteins is highly associated with metastatic
melanoma as well as progression of breast, prostate, pancreatic cancers (Xie, Nakachi et
al. 2001, Yang, Tuxhorn et al. 2005, Dornhofer, Spong et al. 2006, Sun, Wang et al.

100

2008, Sha and Leask 2011). Additionally, high levels of CCN1 and CCN2 can be
stimulated in stromal tissues by tumourigenesis related inflammation (Coussens and
Werb 2002, Leask and Abraham 2006, Wong and Rustgi 2013). We have previously
demonstrated the importance of CCN2 expression in the tumour stroma for facilitating
the metastasis of melanoma (Hutchenreuther, Vincent et al. 2015). In vitro, CCN1 has
similar functions to CCN2 and in vivo, CCN1 is also induced during tissue repair and
fibrosis in a similar pattern to CCN2 (Chen, Mo et al. 2001, Leivonen, Hakkinen et al.
2005, Liu, Thompson et al. 2014). Additionally, CCN1 is induced in response to
hypoxia in early melanomas and is constitutively overexpressed in advanced melanomas;
CCN1 knockdown in human melanoma cells reduces cell adhesion to the integrin Very
Late Antigen 4 (Kunz, Moeller et al. 2003, Schmitz, Gerber et al. 2013). While this
suggests that CCN1 is active in melanoma progression it is unclear whether CCN1 is
instrumental in metastasis, or what the mechanism behind its role may be.
In this report, we use C57 BL6 mice with a conditional deletion of CCN1 in fibroblasts
and a syngeneic B16F(10) murine melanoma model (Wack, Kirst et al. 2002) to
investigate the effect of stromal CCN1 deficiency on melanoma invasion and metastasis.

4.2

Methods

4.2.1 Cell culture and Western Blotting
B16(F10) murine melanoma cells were purchased (ATCC) and cultured in high glucose
Dulbecco's Modified Eagle's Medium (DMEM), 10% fetal bovine serum (FBS) and 1%
antibiotic/antimycotic solution (Invitrogen). Cells were cultured until confluence prior
to harvesting for mRNA or protein extraction. CCN1 levels were evaluated by coincubating cultures with 50µg/mL sodium heparin (Sigma). Sodium heparin was
included to prevent rapid internalization and degradation of CCN1 via low density
lipoprotein receptor-related protein 1 (LRP1) as endogenous CCN1 interacts similarly
with LRP1 as CCN2 , which can be rapidly degraded by mouse cells (Segarini, Nesbitt et
al. 2001, Juric, Chen et al. 2012). 1mL conditioned culture media was collected for every
treatment, and total protein were concentrated using methanol/chloroform precipitation as
previously described (Friedman, Hoving et al. 2009). The concentration of protein was
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detected (Pierce) and equal amounts of protein (50 g) were subjected to SDS/PAGE on
a 10% TGX Stain-Free FastCast acrylamide gel (BioRad). Gels were then exposed to
UV to activate stain-free labelling of protein, and blotted onto nitrocellulose (BioRad)
and CCN1 was detected using a goat anti-CCN1 antibody (1:200 dilution, Santa Cruz)
followed by a HRP-conjugated anti-rabbit antibody (1:2000; Jackson), a
chemiluminescent detection kit (Pierce) and X-Ray film (Kodak). When indicated, cells
were transfected with CYR61 (CCN1) shRNA, CTGF (CCN2) shRNA, or control
shRNA Lentiviral Particles (Santa Cruz) using polybrene and selected for using
puromycin as described by the manufacturer (Santa Cruz).

4.2.2 Real Time RT-PCR
B16(F10) murine melanoma cells were grown in high glucose DMEM containing 10%
FBS until 75% confluence after which the media was replaced with low glucose DMEM
containing 0.5% FBS and grown for 24 hours. RNA was harvested using Trizol
(Invitrogen) and used for Real-Time RT-PCR. 25ng of RNA was reverse transcribed
using qScript cDNA Supermix (Quanta Biosciences) and amplified using PerfeCTa
SYBR Green FastMix and primers for genes of interest (Table 1) using the ABI Prism
7900 HT sequence detector (Applied Biosystems) according to manufacturer's
instructions. Samples were run in triplicate, expression values were standardized to
control values from β-actin primers using ΔΔCt method. Statistical analysis was done
using Student's T-test on GraphPad.

4.2.3 Expression Profiling
Expression profiling was performed as described in prior publications (Guo, Carter et al.
2011, Guo, Carter et al. 2011, Hutchenreuther, Vincent et al. 2015) All sample labeling
and processing was handled at the London Regional Genomics Centre (Robarts Research
Institute, London, Ontario, Canada; http://www.lrgc.ca). Briefly, RNA quality was
assessed on an Agilent 2100 Bioanalyzer (Agilent Technologies Inc.) and the RNA 6000
Nano kit (Caliper Life Sciences) before 5.5 μg of single-stranded cDNA was synthesized
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Target
Β-actin
CCN1
P4Ha1
LOX
PLOD2
COL1a1
α-SMA

Forward
CACTGTCGAGTCGCGTCC
TCTGCGCTAAACAACTCAACGA
AAATGGGTATCCAACAAATGGC
ACTTCCAGTACGGTCTCCCG
CAGGAACATGGGCATGGATTTC
CGATGGATTCCCGTTCGAGT
CATCCGACACTGCTGACA

Reverse
TCATCCATGGCGAACTGGTG
GCAGATCCCTTTCAGAGCGG
GTGCGTTAGAGGACAACAGGA
GCAGCGCATCTCAGGTTGT
GACGTGTCACAAGAGGAGCAA
GAGGCCTCGGTGGACATTAG
AGGTCTCAAACATAATCTGGGTCA

Table 1: Probes/Primers used in real time PCR
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from 200 ng of total RNA, end-labeled, and hybridized, for 16 hours at 45 °C, to Human
Gene 1.0 ST arrays. GeneChips were scanned with the GeneChip Scanner 3000 7G and
probe level (.CEL file) data were generated using Affymetrix Command Console v3.2.4.
Probes were summarized to gene level data in Partek Genomics Suite v6.6 (Partek) using
the RMA algorithm. Experiments were performed twice, and fold changes and P-values
were generated using analysis of variance in Partek. Genes that significantly changed (at
least 1.5 fold change, P-value <0.05) in response to CCN1 knockdown were compiled
and exported into DAVID (http://david.abcc.ncifcrf.gov/) for further analysis.

4.2.4 In vitro invasion assay
10,000 CCN1 shRNA, and control shRNA B16(F10) cells were seeded in growth
medium containing 0.5% FBS (and 5μg/mL puromycin hydrochloride for shRNA cells)
onto a transwell filter insert with a pore size of 8 μm coated with 100μL of 10μg/mL
purified bovine collagen (Advanced Biosystems) as previously described (Chen 2005).
The transwell filter insert was suspended in a plate filled with growth medium containing
10% FBS (to create a chemotactic incentive to invade) and allowed to incubate at 37°C
for 24 hours. After incubation all excess collagen and non-invasive cells were removed
from the inside of the transwell filter insert. The remaining cells were fixed in methanol,
and stained with 1μg/mL DAPI to allow for counting with microscopy.

4.2.5 Animals
Mice possessing a tamoxifen-dependent Cre recombinase under the control of a
fibroblast-specific regulatory sequence from the proα2(I) collagen gene (Zheng, Zhang et
al. 2002) were crossed with mice homozygous for a conditional CCN1 allele or a
conditional CCN2 allele (Liu, Thompson et al. 2014) to generate Cre/CCN1 or
Cre/CCN2 heterozygote mice, which were mated to generate mice hemizygous for Cre
and homozygous for CCN1 or mice hemizygous for Cre and homozygous for CCN2.
Animals used for experiments were genotyped by polymerase chain reaction (PCR) as
described previously (Zheng, Zhang et al. 2002, Liu, Shi-wen et al. 2011). To delete
CCN1 (CCN1-/-) or CCN2 (CCN2-/-) in fibroblasts, 3-week-old mice were given
intraperitoneal injections of tamoxifen suspension (0.1 ml of 10 mg/mL 4-
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hydroxitamoxifen, Sigma) over 5 days. Littermate mice of identical genotype were
injected with corn oil and were used as controls (CCN1fl/fl or CCN2fl/fl). All animal
protocols were approved by the animal care committee at the University of Western
Ontario.

4.2.6 In vivo tumour growth and metastasis
Subconfluent melanoma cells in the exponential growth phase were harvested by
exposure to 0.25% trypsin/0.02% EDTA solution, resuspended in serum-free DMEM at a
concentration of 3300 cells/µL, and 330,000 cells were injected subcutaneously into the
right flank of each mouse. Upon appearance of a palpable tumour the volume of the
tumour was measured daily using calipers and the following equation: Tumour Volume
(mm3) = 1/2(Length of Longest Tumour Dimension) x (Length of Narrowest Tumour
Dimension)2. Tumour growth was evaluated over the course of 14 days, and mice were
euthanized on the 14th day. After euthanasia the lungs and tumour were collected from
the mice and fixed in a 4% paraformaldehyde solution. After fixation, tissues were
processed, embedded in paraffin, and prepared for histological sectioning. Lung sections
were stained with hematoxylin and eosin (H&E; Fisher Scientific) to locate dense
metastatic foci. Three non-serial sections per lung were examined.

4.2.7 Immunohistochemistry
Tumour tissue was stained for CCN1 using the Vectastain ABC Kit (Vector
Laboratories). Briefly, sections (0.5 μm) were cut using a microtome (Leica), collected
on Superfrost Plus slides (Fisher Scientific), de-waxed in xylene, and rehydrated by
successive immersion in descending concentrations of alcohol. Antigen retrieval was
performed by immersing slides in Na-citrate solution (pH 6.0) for 30 minutes at 98°C.
After cooling, slides were rinsed, and non-specific binding was blocked by incubation
with diluted normal serum. Sections were incubated with primary antibodies in diluted
normal serum (1:100 rabbit anti-CCN1; Santa Cruz), followed by incubation with
biotinylated secondary antibody solution and Vectastain ABC Reagent. After
incubations, the sections were incubated in ImmPACT DAB peroxidise substrate (Vector
Laboratories) and counterstained with hematoxylin. Tumour tissue was stained for
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CCN2 by immunofluorescent immunohistochemistry as previously described (Liu and
Leask 2013). Briefly, sections (0.5 μm) were cut using a microtome (Leica), collected on
Superfrost Plus slides (Fisher Scientific), de-waxed in xylene, and rehydrated by
successive immersion in descending concentrations of alcohol. Antigen retrieval was
performed by immersing slides in Na-citrate solution (pH 6.0) for 30 minutes at 98°C.
After cooling, slides were rinsed, and non-specific binding was blocked by incubation
with 10% serum in 0.1% Triton X-100 in PBS for 1 hour and then in primary antibody
(1:100 goat anti-CCN2; Santa Cruz) in 10% serum in 0.1% Triton X-100 in PBS
overnight in a humidified chamber at 4°C overnight.

4.2.8 Proteomic analysis of skin
Skin from CCN1fl/fl and CCN1-/- mice was harvested, minced, and protein was dissolved
in 8M urea. After eight-fold dilution with 50 mM NH4HCO3, pH 7.8, tryptic digestion
was carried out for 18 h at 37°C, after the addition of 2% (w/w) sequencing-grade trypsin
(Promega, Madison, WI, USA).
Peptide separation and mass spectrometric analyses were carried out with a nano-HPLC
Proxeon (Thermo Scientific, San Jose, CA, USA) which allows in-line liquid
chromatography with the capillary column, 75 µm×10 cm (Pico Tip™ EMITTER, New
Objective, Woburn, MA) packed in-house using Magic C18 resin of 3 µm diameter and
200 Å pores size (Michrom BioResources, Auburn, CA) linked to mass spectrometer
(LTQ-Velos, Thermo Scientific, San Jose, CA, USA) using an electrospray ionization in
a survey scan in the range of m/z values 390–2000 tandem MS/MS. Equal amount of all
samples were dried by rotary evaporator and re-suspended in 20 µl of 97.5 % H2O/2.4%
acetonitrile/0.1% formic acid and then subjected to reversed-phase LC-ESI-MS/MS. The
nano-flow reversed-phase HPLC was developed with linear 85 minutes gradient ranging
from 5% to 55% of solvent B in 65 minutes (97.5% acetonitrile, 0.1% formic acid) at a
flow rate of 200 nl/min with a maximum pressure of 280 bar. Electrospray voltage and
the temperature of the ion transfer capillary were 1.8 kV and 250°C respectively. Each
survey scan (MS) was followed by automated sequential selection of seven peptides for
CID, with dynamic exclusion of the previously selected ions.
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The obtained MS/MS spectra were searched against human protein databases (Swiss Prot
and TrEMBL, Swiss Institute of Bioinformatics, Geneva, Switzerland,
http://ca.expasy.org/sprot/) using SEQUEST algorithm in Proteome Discoverer 1.3
software (Thermo Scientific, San Jose, CA, USA). Search results were filtered for a False
Discovery rate of 1% employing a decoy search strategy utilizing a reverse database. An
addition inclusion criterion for positive identification of proteins was that the same
protein passing the filter score from at least in three different MS analyses from the same
group in a total of four MS analyses per group.
For quantitative proteome analysis, three MS raw files from each pooled group were
analyzed using SIEVE software (Version 2.0 Thermo Scientific, San Jose, CA, USA).
Signal processing was performed in a total of 12 MS raw files. The SIEVE experimental
workflow was defined as “Control Compare Trend Analysis” where one class of samples
are compared to one or more other class of samples. Here the control samples were
compared to each of the samples that were treated with different percentages of NaF (1%,
2% and 5%). For the alignment step, a single MS raw file belonging to the HA group was
selected as the reference file and all of the other files were adjusted to generate the best
correlation to this reference file. After alignment, the feature detection and integration (or
framing) process was performed using the MS level data with a feature called “Frames
From MS2 Scans” only. When using this type of framing only MS mass-to-charge ratio
(m/z) values that were associated with MS2 scan are used. Any m/z measurements that
do not have MS2 were ignored. The parameters used consisted of a frame m/z width of
1500 ppm and a retention time width of 1.75 min. A total of 216,099 MS2 scans were
present in all of the 12 RAW files that resulted in a total of 20,158 frames. Then peak
integration was performed for each frame and these values were used for statistic
analysis. Next, peptide sequences obtained from the database search using SEQUEST
algorithm in Proteome Discoverer 1.3 were imported into SIEVE. A filter was applied to
the peptide sequences during the import that eliminated all sequences with a Percolator qvalue greater than 1% (false discovery rate). Peptides were grouped into proteins and a
protein ratio and p-value were calculated. SIEVE uses a weighted average of the peptide
intensities for the protein calculation. By using the weighted average, peptides with lower
variance in their intensity measurements have a higher weight on the overall protein ratio.
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This is done to decrease variance in protein level quantities based on variance of the
peptides that compose proteins

4.2.9 Transmission Electron Microscopy of skin
Skin from CCN1fl/fl and CCN1-/- mice was harvested and cut into 0.5-1.0mm wedges,
then fixed in 2.5% gluteraldehyde in cacodylate buffer overnight. Tissues were oriented
and immobilized using mPREP system and workbench. All subsequent steps were
conducted in mPREM system. Tissue was fixed/stained in 1% osmium tetroxide in
cacodylate buffer (0.1M, pH 7.2) for 1 hour on ice, then rinsed 5 times in ddH2O. Tissue
was stained in 1% Tannic acid in cacodylate buffer for 2 hours on ice, then again in fresh
1% Tannic acid in cacodylate buffer for 2 more hours on ice. Samples were rinsed 5
times in ddH2O, then incubated in 1% uranyl acetate at 4°C overnight in the dark.
Samples were rinsed 5 times in ddH2O before being dehydrated in successive baths of
20%, 50%, 70%, 90%, 95%, and 3 times in 100% acetone. After dehydration, samples
were infiltrated overnight by mixtures of 1 part Epon-Araldite resin:2 parts acetone
followed by 1 part resin:1 part acetone, followed by 2 parts resin:1 part acetone, followed
by 100% resin. Samples were embedded in 100% resin, which was polymerized in 60°C
oven for 5 days. Embedded samples were sectioned to a thickness of 70-80nm on the
Ultracut E (Reichert-Jung) and collected on nickel grids. Grids were stained with 1%
uranyl acetate for 15 minutes, rinsed 24 times before staining with Reynolds' lead citrate.
Grids were rinsed 24 more times before being dried. Images were obtained on a Philips
CM10 transmission electron microscope at 60 Kv.

4.3

Results

4.3.1 CCN1 is not regulated by CCN2 expression in B16F(10) murine
melanoma cells or tumour stroma, and its loss decreases
expression of different genes
Initial experiments were conducted in which B16F(10) melanoma cells were stably
transfected with either CCN1 shRNA, CCN2 shRNA, or scrambled control shRNA.
Extent of CCN1 knockdown relative to β-actin control was determined by real time PCR
and Western Blot analyses (Figure 1A and 1B), and mRNA expression profiling was
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performed using Human Gene 1.0 ST arrays. Genes reduced by CCN1 knockdown were
compared to previously generated expression data of B16F(10) cells transfected with
CCN2 shRNA (Hutchenreuther, Vincent et al. 2015) (Figure 2A). Additionally, CCN1
expression of CCN2 shRNA transfected cells was assayed by real time PCR (Figure 2B),
and stromal CCN1 expression of cells implanted in mice with or without CCN2
expression in fibroblasts was detected by immunohistochemistry (Figure 2C).
Expression profiling data revealed very little overlap (44/1117 genes downregulated
total) in genes downregulated by both CCN1 and CCN2 loss in B16F(10) melanoma
cells. Additionally, there was no significant difference in CCN1 mRNA expression from
cells transfected with CCN2 shRNA, and stromal expression of CCN1 in C57 BL6 mice
implanted with B16F(10) melanoma cells was still detected in mice lacking CCN2 in
their fibroblasts.

4.3.2 Loss of CCN1 expression by B16F(10) murine melanoma cells
results in impaired invasion
To assess the invasive ability of CCN1 deficient melanoma cells, B16F(10) melanoma
cells that were transfected with either CCN1 shRNA or scrambled control shRNA were
subjected to a transwell filter invasion assay. After incubation for 24 hours at 37°C, noninvasive cells and collagen were removed from the transwell membrane before it was
mounted and cells were counted. Cells transfected with CCN1 shRNA showed
significantly less invasion through type I collagen than cells transfected with scrambled
control shRNA (Figure 1C).
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Figure 4-1 CCN1 knockdown impairs invasion through collagen
B16(F10) melanoma cells were transfected with CCN1 shRNA, to produce a knockdown
in Ccn1 mRNA expression, or a scrambled shRNA, to act as a control. (a) Cells treated
with CCN1 shRNA lentiviral particles showed a significant decrease in Ccn1 mRNA
expression compared with cells treated with scrambled control shRNA (n = 3, p<0.001),
and (b) reduced CCN1 protein present in growth media (Santa Cruz, sc-13100). (c) Both
cell lines were subjected to a Boyden chamber assay to assess their ability to invade
through a collagen matrix. After being given 24 hours to invade through collagen
towards a chemotactic incentive, the non-invasive cells and collagen were removed.
Invasive cells were stained with DAPI (4’6-diamidino-2-phenylindole). Cells deficient in
CCN1 were significantly less invasive (n = 3, p<0.001).
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Figure 4-2 CCN1 likely acts through a different mechanism than, and is not
regulated by CCN2 expression
B16(F10) melanoma cells were transfected with either CCN2 short hairpin RNA
(shRNA), to produce a knockdown in Ccn2 mRNA expression, CCN1 shRNA, to
produce a knockdown in Ccn1 mRNA expression, or a scrambled shRNA, to act as a
control. (a) mRNA collected from cells was analyzed by microarray on the Human Gene
1.0 ST array (Affymetrix) to generate lists of genes with at least 1.5 fold decreased
expression using Partek Genomics Suite v6.6 (Partek) when either CCN1 or CCN2 are
knocked down. The majority of genes decreased by either CCN1 or CCN2 knockdown
were exclusive. (b) Cells treated with CCN2 shRNA showed no significant reduction in
Ccn1 mRNA expression, and (c) sections of tumour stroma from wild-type or Ccn2knockout mice both stain positively for CCN1 expression in tumour stroma (Santa Cruz,
sc-13100; n = 3, representative sections shown).
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4.3.3 Loss of CCN1 expression by tumour stroma resulted in
impaired metastasis in vivo
In order to determine if the invasive defect observed in vitro was seen in vivo as well we
used a syngeneic model wherein we implanted B16F(10) melanoma cells (which are
derived from C57 BL6 mice) subcutaneously into the right flank of C57 BL6 mice that
had CCN1 deleted or not in their fibroblasts. Cells were suspended in serum-free DMEM
and injected subcutaneously two weeks post-deletion of CCN1 and allowed to form a
palpable tumour. Fourteen days later harvested lungs were sectioned, H&E stained, and
assessed for extent of metastasis (Figure 3). Loss of CCN1 from the tumour stroma
resulted in a significant reduction in metastasis. Loss of CCN1 from tumour stroma was
confirmed by immunohistochemical analysis (Figure 5). These results indicate that
CCN1 in tissue surrounding a tumour is essential for the metastasis of melanoma.

4.3.4 Loss of CCN1 expression by fibroblasts resulted in impaired
collagen organization
In unpublished data generated by Katherine Quesnel of the Leask lab at the University of
Western Ontario, mRNA was extracted from skin samples of wild-type and CCN1deficient mice (mice deleted for CCN1 in the fibroblasts) and analyzed by real time PCR.
Skin from CCN1-deficient mice showed a significantly reduced expression of mRNA
encoding the collagen crosslinking enzymes prolyl 4-hydroxylase subunit alpha-1, lysyl
oxidase, and lysyl hydroxylase 2 (translated from P4Ha1, LOX, and PLOD2 mRNA), but
no reduction in the amount of type I collagen α1 being transcribed and no difference in
transcription of α-smooth muscle actin, which is a major constituents of the contractile
apparatus (Rockey, Weymouth et al. 2013). To determine if this change in mRNA
expression carried over to a change in translation of functional enzymes, skin protein was
dissolved in urea to solublize collagens, trypsin digested, and analyzed by LC-MS.
Detected fragments were analyzed for hydroxylation of target sites for crosslinking
enzymes, and a significant decrease in the number of potential target sites for PLOD2
modification that were oxidized was detected (Figure 4).
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Figure 4-1 Loss of CCN1 in tumour stroma fibroblasts impairs metastasis in vivo
(a) Representative images of lung sections from wild-type or Ccn1-knockout mice (mice
deleted for CCN1 in fibroblasts) following subcutaneous implantation of B16(F10)
melanoma cells after 14 days of tumour growth. Hematoxylin and eosin (H&E) staining
detects sites of pulmonary metastasis by staining dense metastatic foci purple. (b)
Tumours implanted in Ccn1-knockout mice show a significant decrease in pulmonary
metastasis compared to wild-type (n = 6, p<0.001).
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Figure 4-2 CCN1 Alters Collagen Processing and Stability
Collagen from skin samples collected from wild-type and Ccn1-deficient mice was
solublized in Urea, digested with trypsin, and analyzed by HPLC-Mass Spectrometry.
Ccn1-deficient samples showed a significantly reduced proportion of hydroxylation at
sites targeted by crosslinking enzyme PLOD2 (n = 4, p<0.05). Mass Spectrometry
performed by Yizhi Xiao of the Siqueira lab at University of Western Ontario.
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Figure 4-3 Stromal CCN1 Thickens and Organizes Collagen
Sections of tumour stroma from wild-type or Ccn1-knockout mice (mice deleted for
CCN1 in fibroblasts) stained with anti-CCN1 (Santa Cruz, sc-13100) or Masson’s
trichrome. Ccn1-knockout stroma shows sparse blue staining, indicating a reduction in
collagen, compared to wild-type stroma.
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To determine the effects of CCN1 deletion from fibroblasts on the collagen architecture
of the skin samples from wild-type and CCN1-deficient mice were analyzed by
transmission electron microscopy after fixation and staining with uranyl acetate, osmium
tetroxide, tannic acid, and Reynolds' lead citrate. High magnification cross-sectional
images were used to measure the diameter of collagen fibrils (Figure 6), and lower
magnification images were used to assess collagen fibre organization (Figure 7). Skin
samples from CCN1-deficient mice had significantly reduced collagen fibril diameter
compared to wild-type samples (Figure 6B), with the presence of abnormal interstitial
spaces between fibrils making up a fiber (Figure 6A). CCN1-deficient mice also had
highly disorganized collagen that failed to form thick, directional, organized fibres
(Figure 7). To determine if these results were also seen in the stroma recruited by a
primary melanoma tumour, sections of tumours harvested from wild-type and CCN1deficient mice were stained for CCN1 expression to verify stromal CCN1 deletion, and
by Masson's Trichrome which stains collagen fibres blue (Figure 5). Trichrome stains of
CCN1-deficient mice showed a tumour stroma with more diffuse collagen than the thick,
interwoven fibres formed by the stroma in the wild-type mouse.

4.4

Discussion

Our results demonstrate that CCN1 from the fibroblasts of the tumour stroma is required
for the formation of an organized collagen matrix, and for melanoma metastasis. This is
consistent with the concept that the cancer associated fibroblasts reshape the tumour
microenvironment to encourage tumour cell invasion. This reinforces the idea that
targeting the alterations to the stromal microenvironment induced by the tumour might be
a viable strategy to develop widely effective anti-cancer therapies (Jewer, Findlay et al.
2012).
CCN1 is a member of the CCN family of matricellular proteins, and shows a high degree
of spatiotemporal regulation due to its role as a regulatory molecule in the extracellular
environment (Leask and Abraham 2006). In normal skin CCN1 shows low expression,
but during wound healing is highly upregulated, secreted to the extracellular matrix
where it

121

122

Figure 4-4 Loss of CCN1 decreases collagen fibril diameter
Sections of skin from wild-type or Ccn1-knockout mice (mice deleted for CCN1 in
fibroblasts) were fixed and stained with gluteraldehyde, tannic acid, uranyl acetate, and
Reynold’s lead citrate. Samples were cut into ~70nm sections and imaged by
transmission electron microscopy. (a) Representative cross-sectional images of collagen
fibrils from wild-type and Ccn1-knockout mice, with diameter distribution graphs. Note
the presence of interstitial spaces within each bundle of fibrils in Ccn1-knockout mice
(indicated by arrows). (b) Average fibril diameter was significantly decreased in Ccn1knockout mice compared to wild-type (n = 3, p<0.01)

123

124

Figure 4-5 Loss of CCN1 decreases organization of collagen fibrils into fibers
Sections of skin from wild-type or Ccn1-knockout mice (mice deleted for CCN1 in
fibroblasts) were fixed and stained with gluteraldehyde, tannic acid, uranyl acetate, and
Reynolds lead citrate. Samples were cut into ~70nm sections and imaged by
transmission electron microscopy. Collagen fibrils from Ccn1-knockout mice do not
form organized, directional fibers like those seen in wild-type samples.

125

remains tightly associated with the tissue that produced it, and through integrin signaling
and potentiation of other cytokine signaling it increases adhesion and migration in
fibroblasts, as well as increasing angiogenic activity in endothelial cells (Chaqour and
Goppelt-Struebe 2006, Lau 2011). In pathological conditions, CCN1 has been shown to
play a role in inflammatory and fibrotic processes, as has been upregulated in fibrosis of
several organs, and overexpression has been detected in a wide variety of cancers (Lai,
Chen et al. 2013, Lai, Lin et al. 2014, Grazioli, Gil et al. 2015, Li, Ye et al. 2015). While
it has been shown to be upregulated few studies have be done to elucidate the specific
mechanisms by which CCN1 acts in cancers, but in melanoma CCN1 has been implicated
in activation of the integrin VLA-4 in melanoma cells to increase their ability to
extravasate at the site of metastasis, and in osteosarcoma CCN1 increases invasion and
metastasis through integrin signaling (Schmitz, Gerber et al. 2013, Barreto, Ray et al.
2016). Our in vitro data showing that CCN1 deficient B16F(10) cells have impaired
invasion through type I collagen are consistent with this, and suggesting that CCN1 might
increase invasion through integrin signaling in melanoma as well. While CCN2 is known
to upregulate genes associated with the deposition of new extracellular matrix in fibrotic
stroma, including stimulating increased production of collagen, CCN1 has not typically
been associated with such processes (Quan, Xu et al. 2014). This is understandable,
given our data showing that loss of CCN1 does not affect the transcription of type I
collagen, but the two proteins may act in concert by performing different functions to
facilitate the accumulation of extracellular matrix proteins, with CCN2 increasing the
production of collagen and CCN1 increasing the production of collagen cross-linking
enzymes to stabilize and mature the collagen after production. The process of
crosslinking is integral to the formation of a thick, patterned extracellular matrix that uses
mechanical transduction to induce invasive phenotypes in cancer cells (Levental, Yu et
al. 2009).
In summation, our in vitro invasion data are consistent with the hypothesis that CCN1
stimulates melanoma invasion through integrin signaling, and also shows that CCN1 is
required for proper collagen matrix formation and melanoma metastasis. These data
indicate that CCN1 is a potential target for disrupting the formation of a pro-metastatic
tumour stroma, and is thus a novel approach to mitigate the progression of melanoma.
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Chapter 5

5

Discussion

Melanoma is a highly invasive cancer with an increasing incidence that is responsible for
a disproportionately large number of skin cancer fatalities for its incidence of diagnosis
(Reed, Brewer et al. 2012). The two major reasons for its high rate of fatalities are that it
is highly metastatic, and its high resistance to conventional anti-cancer therapies like
chemo- and radiotherapy due to its melanocytic origins (Soengas and Lowe 2003). Even
newly developed therapies targeting the mutations driving tumours, such as inhibition of
mutant BRAF, show little efficacy as almost all tumours eventually acquire therapy
resistance (Lim, Menzies et al. 2017). One prominent theory as to the source of this
resistance is that tumour cell interaction with stromal extracellular matrix components
activates survival signaling through the extracellular matrix association with integrin β1,
which activates phosphoinositide 3-kinase (PI3K) signaling which compensates for the
loss of constitutive BRAF activation (Hirata, Girotti et al. 2015).
Additionally, melanoma shows low susceptibility to anti-angiogenic therapies, with no
studies showing a significant increase in overall survival in metastatic melanoma patients
(Felcht and Thomas 2015). The reasons for therapeutic failure are multifactorial, but
have been shown to include the infiltration of tumour stroma such as by endothelial
progenitor cells, immature myeloid cells, and cancer associated fibroblasts all of which
can promote the activation of alternate pro-angiogenic signaling pathways (Pastushenko,
Vermeulen et al. 2014, Lupo, Caporarello et al. 2016). In addition to renewed
angiogenesis, tumours can resist anti-angiogenic therapy by vasculogenic mimicry, where
tumour cells themselves form a vascular network that compensates for a lack of sprouting
angiogenesis as well as providing an easy route into the circulatory system for metastasis
(Hendrix, Seftor et al. 2003, Felcht and Thomas 2015).
While these vasculogenic networks are formed from tumour cells, the extent of their
composition and formation has been shown to depend on interactions with the tumour
stroma. Mesenchymal stem cells can be reprogrammed into an endothelial cell-like
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phenotype by melanoma, and the degree of vasculogenic mimicry in melanoma in vitro
and in vivo can be reduced by inhibition of matrix metalloproteinase (MMP) 2 (Bergers
and Hanahan 2008, Vartanian, Karshieva et al. 2016, Liang, Sun et al. 2017, Wang, You
et al. 2017). Treatment of dermal fibroblasts with conditioned media from melanoma
cells promotes myofibroblast differentiation, which among other things increases MMP2
secretion, and the treatment of melanoma cells with conditioned media of cells with a
secretory phenotype similar to the activated fibroblasts of the stroma results in increased
MMP2 expression in melanoma cells (Albinet, Bats et al. 2014, Menicacci, Laurenzana et
al. 2017). These results indicate that the stroma is instrumental in vasculogenic mimicry,
which is consistent with the emerging concept that alterations in the tumour
microenvironment play a major role in the progression, survival, and metastasis of
tumours (Jewer, Findlay et al. 2012, Quail, Taylor et al. 2012).
The CCN proteins are a family of matricellular proteins that are highly spatiotemporally
regulated, with CCN1 and CCN2 showing low basal expression in adult fibroblasts that is
significantly increased during wound healing and fibrosis (Leask and Abraham 2006).
Additionally, abnormal expression of CCN1 and CCN2 have been associated with
progression of malignant melanoma, breast, prostate, and pancreatic cancers (Xie,
Nakachi et al. 2001, Yang, Tuxhorn et al. 2005, Dornhofer, Spong et al. 2006, Sha and
Leask 2011). A large source of increased CCN protein expression is from activated
cancer associated fibroblasts, which adopt a phenotype similar to the myofibroblasts seen
in fibrosis (Albinet, Bats et al. 2014). Given that CCN2 is required for the development
of fibrosis, CCN1 has been shown to have similar functions to CCN2 in vitro and similar
expression patterns in tissue repair and fibrosis in vivo we used both shRNA in vitro and
genetic knockouts in vivo to investigate the roles of CCN1 and CCN2 in melanoma
(Chen, Mo et al. 2001, Leivonen, Hakkinen et al. 2005, Liu, Parapuram et al. 2013, Liu,
Thompson et al. 2014).
In this thesis I found that knockdown of both CCN1 and CCN2 in B16F(10) melanoma
cells each reduced the ability of the cells to invade through type I collagen. This is
consistent with literature showing that CCN1 increases invasion in osteosarcoma, breast
cancer, and pancreatic cancer, while CCN2 and invasion both increase in response to
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increased YAP/TAZ signaling (Haque, Mehta et al. 2011, Jim Leu, Sung et al. 2013,
Nallet-Staub, Marsaud et al. 2014, Nguyen, Song et al. 2016). Additionally, since the
time of initial publication of my results it has been shown that CCN2 derived from
mesenchymal stem cells increases in vitro invasion of squamous cell carcinoma (Wu, Li
et al. 2017). Interestingly, while CCN1 has been shown to increase invasion in other
cancers, it has previously been shown to decrease invasion in melanoma (Dobroff, Wang
et al. 2009). Dobroff et al. showed that overexpression of CCN1 in highly invasive
melanoma cells decreased their ability to invade through Matrigel, and knockdown of
CCN1 increased their invasive ability. This is potentially explained by differences in
methodologies used between their study and mine. The composition of Matrigel is very
similar to that of the basement membrane separating the epidermis and the dermis, with
its primary collagen being type IV while my experiments measured the ability of cells to
invade through type I collagen, which is the dominant form of collagen found in the
dermis (Hughes, Postovit et al. 2010, Krieg and Aumailley 2011). Thus, it is possible
that CCN1 impedes the ability of melanoma cells to invade through the basement
membrane, but once invasion has happened it enhances the ability of cells to invade
rapidly through the dermis.
Given the similar in vitro functions of CCN1 and CCN2 and their similar patterns of in
vivo expression in wound repair and fibrosis it was speculated that the genes might have
similar functions in melanoma progression as well, however when the gene expression
alterations of B16F(10) melanoma cells transfected with CCN2 shRNA were compared
to those of cells transfected with CCN1 shRNA I found that there was very little overlap
in genes with reduced expression. This suggests that while loss of CCN1 and CCN2 both
reduced invasive capacity of cells in vitro, they are likely acting through a different
mechanism. Previous studies indicate that CCN1-induced increases in melanoma
invasion are likely a result of integrin signaling, as shown by the blockade of αV integrin
activation by CCN1 resulting in decrease in invasion in breast cancer and blockade of
CCN1 associating with the integrin VLA-4 resulting in a decrease in invasion in
melanoma (Jim Leu, Sung et al. 2013, Schmitz, Gerber et al. 2013), but the mechanisms
through which CCN2 increases metastasis are less well established. Our results showing
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CCN2 induces invasion through increased expression of periostin (POSTN) are
consistent with previous observations that POSTN expression correlates with metastasis
in several cancers, promotes invasiveness in pancreatic cancer cells, and that recombinant
CCN2 can induce POSTN expression in periodontal ligament cells (Asano, Kubota et al.
2005, Baril, Gangeswaran et al. 2007, Tilman, Mattiussi et al. 2007, Kotobuki, Yang et
al. 2014).
When B16F(10) melanoma cells with CCN2 knockdown or not were implanted into
syngeneic C57 BL6 mice with CCN2 deleted in fibroblasts or not I found that loss of
CCN2 in the fibroblasts significantly impaired the metastasis of the tumour. This is
consistent with previous studies showing that not only are high levels of CCN2 a
prognositic factor for aggressive pancreatic cancer, but also that antibodies blocking
CCN2 block anchorage independent growth in vitro and significantly reduce metastasis
of pancreatic cancer in vivo (Dornhofer, Spong et al. 2006, Bennewith, Huang et al.
2009). Additionally, high levels of stromal CCN2 expression are poor prognostic
markers in glioma, pancreatic, and prostate cancers (Wells, Howlett et al. 2015).
Interestingly, the co-culture of squamous cell carcinoma cells with mesenchymal stem
cells induced increase expression of CCN2 in the mesenchymal stem cells that in turn
enhanced the invasion of the cancer cells in vitro (Wu, Li et al. 2017). In multiple
cancers, including melanoma, CCN2 is upregulated by hypoxia and by YAP/TAZ/Hippo,
and suppression of YAP-TEAD complex activity in ovarian cancer using verteporfin
decreased CCN2 expression without significantly affecting expression of upstream Hippo
components yielding a decreased volume of gross ascites in preclinical models
(Minchenko, Kharkova et al. 2014, Nallet-Staub, Marsaud et al. 2014, Feng, Gou et al.
2016). These data support my findings that stromal CCN2 is essential for the metastasis
of melanoma and suggest that depriving the tumour of stromal CCN2 is a viable therapy
to reduce the metastasis of melanoma.
Loss of CCN2 from the fibroblasts of the mouse did not significantly alter the recruitment
of resident synthetic fibroblasts to the tumour stroma, but it did reduce the proportion of
stromal cells expressing stemness marker SOX2, and also almost completely eliminated
αSMA expression in the stroma which is indicative of the activation of myofibroblasts
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(Hinz 2016). This is significant because activation of fibroblasts in the tumour stroma has
been shown to cause increased matrix metalloproteinase secretion, increased expression
of TGFβ, tenascin C, POSTN, and cytokines that recruit more cells to the activated
stroma (Horimoto, Polanska et al. 2012, Kalluri 2016). Loss of CCN2 preventing
activation of the tumour stroma also serves to further link together the stromal
microenvironment and fibrosis, as it establishes that in both pathologies fibroblasts are
differentiated into myofibroblasts in a CCN2 dependent fashion that differs from that
seen in normal wound repair (Liu, Shi-wen et al. 2011, Liu, Parapuram et al. 2013, Liu,
Thompson et al. 2014). The impaired induction of both αSMA and SOX2 as well as the
reduced pulmonary metastasis in the absence of stromal CCN2 are consistent with the
findings of Herrera et al that cancer associated fibroblasts expressing high levels of
αSMA and stemness markers like SOX2 correlate with the induction of a strong promigratory effect in cancer cells by the stroma (Herrera, Islam et al. 2013).
Another finding of this study is that tumours lacking CCN2 in the fibroblasts of their
stroma have significantly reduced vasculature. This is consistent with prior studies
showing that CCN2 is upregulated by hypoxia, promotes endothelial cell proliferation
and tubule formation, and induces VEGF expression through hypoxia inducible factor
(HIF)-1α-dependent pathways (Leask and Abraham 2006, Jun and Lau 2011, Mongiat,
Andreuzzi et al. 2016). Additionally, recombinant CCN2 applied to corneas promotes
angiogenesis, and CCN2 null mice die shortly after birth and show vascular defects
(Leask and Abraham 2006). CCN2 expression is spatiotemporally correlated with the
expansion of blood vessels seen in repair of ischemic, hyperoxic, and hyperglycemic
injuries (Krupska, Bruford et al. 2015). In agreement with the results of this study
showing CCN2 is strongly correlated with pro-angiogenic gene expression in clinical
patients CCN2 blocking antibodies have been shown to prevent angiogenesis and the
formation of microvasculature in pancreatic and breast cancer models (Aikawa, Gunn et
al. 2006, Shimo, Kubota et al. 2006).
B16F(10) cells with CCN2 knockdown showed a reduction in secreted pro-angiogenic
proteins. Reduced VEGFa and type I collagen α1 secretion were confirmed by ELISA of
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conditioned media. VEGFa is highly expressed in most cancers, and is one of the primary
molecules involved in driving angiogenesis (Pastushenko, Vermeulen et al. 2014). In
addition, cells with higher expression of VEGF and its receptors have been shown to
have a greater capacity for vasculogenic mimicry, and blockade of VEGF in vitro has
been shown to inhibit tubule formation associated with vasculogenic mimicry in
melanoma, ovarian carcinoma, and osteosarcoma (Vartanian, Burova et al. 2007, Mei,
Gao et al. 2008, Wang, Sun et al. 2008). Additionally, type I collagen has been shown to
be required for the proper formation of capillaries, and has been seen focally in some
intratumoural patterns formed through vasculogenic mimicry and has been shown to have
97-fold increased expression in invasive vasculognic mimicry capable melanoma cells
when compared to cells that are incapable of vasculogenic mimicry (Lin, Maniotis et al.
2005).
Consistent with these facts, this study showed that loss of CCN2 both in vitro and in vivo
reduced vasculogenic mimicry. B16F(10) cells transfected with CCN2 shRNA to
produce a knockdown in CCN2 expression formed fewer tubules in a matrigel-based
tubule formation assay than those transfected with a scrambled control shRNA did,
indicating they have a reduced capacity to form vasculogenic networks. Since
vasculogenic mimicry is associated with poor prognosis in melanoma and is largely
impervious to current anti-angiogenic therapies despite the loss of vasculogenic mimicry
when VEGF is blocked in vitro, the ability to impede its development in vivo is of
potential clinical signifigance (Wang, You et al. 2017).
A novel finding of this study is that reduced vasculogenic mimicry was observed in vivo
when CCN2 was deleted in fibroblasts. C57 BL6 mice expressing either GFP or
TdTomato in all endogenous tissues and with CCN2 deleted or not in fibroblasts had
B16F(10) melanoma cells implanted subcutaneously. Once a tumour had grown, it was
harvested and stained for vWF, a marker expressed in both mouse and tumour derived
vasculature (Dunleavey and Dudley 2012). Not only did tumours with CCN2 deleted in
fibroblasts show reduced vascular area, but they also showed a significantly reduced
proportion of vasculature arising from vasculogenic mimicry. While there has been little
research has been done on the role of activated tumour stroma on inducing a vasculogenic
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mimicry phenotype on tumour cells, with most studies focusing on either the activated
stroma's impact on total vascularization or the tumour's ability to induce vasculogenic
mimicry in non-endothelial stromal cells, these results are consistent with and build upon
the few in vitro studies on cancer cell lines that have been performed. Menicacci et al.
have shown that melanoma cells grown in the conditioned media of fibroblasts with a
similar secretory phenotype to cancer associated fibroblasts show an increase in their
production of matrix metalloproteinase (MMP) 2 (Menicacci, Laurenzana et al. 2017),
and two recent studies independently show that inhibition of MMP2 in vitro reduces
vasculogenic mimicry (Liang, Sun et al. 2017, Wang, You et al. 2017). Additionally,
dermal fibroblasts grown in conditioned medium from melanoma cells differentiate into
myofibroblasts and display increased MMP2 production, representing a potential
additional source of MMP2 to induce vasculogenic mimicry (Albinet, Bats et al. 2014).
The results of this study indicate that, similar to fibrosis, myofibroblast differentiation is
dependent on CCN2, and thus the lack of myofibroblasts in the tumour stroma may be
responsible for the decreased vasculogenic mimicry observed in tumours with CCN2
deleted in their fibroblasts (Liu, Parapuram et al. 2013, Liu, Thompson et al. 2014).
When B16F(10) melanoma cells were implanted into syngeneic mice with CCN1 deleted
in fibroblasts or not I found that loss of CCN1 in the fibroblasts significantly impaired the
pulmonary metastasis of the tumour. This is consistent with literature showing that
CCN1 expression is increased in aggressive or advanced prostate cancer, glioma, breast
cancer, colorectal cancer, ovarian cancer, and osteosarcoma (Leask and Abraham 2006,
Li, Ye et al. 2015, Barreto, Ray et al. 2016). It is worth noting that while these
correlations are well established, and tumour-cell derived CCN1 has been shown to
increase cancer progression through association with αv integrin that to my knowledge no
study has been done directly testing the effects of stromal CCN1 on tumour progression
has been performed (Monnier, Farmer et al. 2008). However, the results of this study are
consistent with the observation that low molecular weight heparin administered to
patients reduces their incidence of metastasis by preventing VLA-4/V-CAM1 binding,
that CCN1 mediates this binding, and that heparin binds to CCN1 and prevents this
mediation (Fritzsche, Simonis et al. 2008, Schmitz, Gerber et al. 2013).
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To determine the mechanism by which the deletion or blockade of CCN1 might prevent
the metastasis of melanoma, skin from mice with CCN1 deleted in their fibroblasts or not
was analyzed. In unpublished work from Katherine Quesnel in our lab, CCN1 deletion in
fibroblasts was shown to reduce the transcription of genes encoding crosslinking
enzymes P4Ha1, LOX, and PLOD2. In order to determine if there was any functional
difference in collagen crosslinking resultant from this decrease, protein from the skin was
dissolved in Urea and analyzed by mass spectrometry. When peptide sequences were
analyzed I found that there was no difference in hydroxylation of sites associated with
P4Ha1 crosslinking, which is consistent with the fact that collagen lacking P4Ha1
crosslinking results in collagens that are not stable at physiological temperatures so any
collagens not crosslinked due to reduced activity would rapidly degrade (Bella 2016), but
there was a significant reduction in the hydroxylation of sites associated with PLOD2
crosslinking. The observed reduction in PLOD2 and its activity is consistent with the
results of previous studies showing that PLOD2 is transcribed in response to SMAD3dependent TGFβ induction, and that CCN1 enhances profibrotic TGFβ/SMAD3 signaling
in myofibroblasts, and that fibroblasts associated with melanoma show a significant
increase in PLOD2 expression (Slany, Meshcheryakova et al. 2014, Kurundkar,
Kurundkar et al. 2016, Du, Pang et al. 2017).
To determine if the lack of PLOD2 activity translated into any defects in collagen
architecture, tumours were stained with Masson's Trichrome. The collagen surrounding
the tumour was more sparse in mice with CCN1 deleted in their fibroblasts than in wild
type. Additionally, skin samples from both types of mice were imaged by transmission
electron microscopy, and mice with CCN1 deleted in their fibroblasts displayed a
significantly reduced collagen fibril diameter, and a lack of organized fibre structure like
that seen in wild type. These results are consistent with previous studies showing that
cancer associated fibroblasts and myofibroblasts organize the collagen of the extracellular
matrix into highly aligned fibers, that the stability of these fibers are primarily mediated
by PLOD2-catalyzed crosslinking that occurs both intracellularly and extracellularly, and
that depletion of PLOD2 from the stroma of melanoma reduces the proinvasive effects of
cancer associated fibroblasts on the tumour (Chen, Guo et al. 2016, Du, Pang et al. 2017).
In fibrotic tissues, excessive PLOD2-catalyzed crosslinking reduces degradation by
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collagenases leading to the accumulation of a stiff matrix (Gjaltema, de Rond et al.
2015). The stiffness of this matrix then serves to stimulate myofibroblast differentiation,
leading to more collagen production in both fibrotic conditions and in cancer associated
fibroblasts (Gjaltema, de Rond et al. 2015, Zhang, Grither et al. 2016). In addition to
further activating the fibroblasts of the stromal microenvironment this stiff matrix can
exert mechanical stress on cancer cells and in doing so reprogram them into more proinvasive phenotypes in prostate cancer, breast cancer, and non-small cell lung cancer
(Zaman, Trapani et al. 2006, Goetz, Minguet et al. 2011, Fenner, Stacer et al. 2014,
Navab, Strumpf et al. 2016).
While these results are consistent with and expand on other work in the literature, there
are some limitations to the experiments used that might impact the translatability of the
results. These results were derived largely from experiments performed in vitro and in
animal models, and as such they might not be directly representative of the processes
occurring in patients due to both the differences between human and mouse physiology
and the differences in genetic diversity between an inbred mouse line and the patients
seen in clinic. Additionally, while the promoter used to achieve knockout of CCN1 and
CCN2 in fibroblasts is specific to fibroblasts in adult mice (Bou-Gharios, Garrett et al.
1996), it is only effective in synthetic fibroblasts, and would not successfully delete
CCN1 or CCN2 in non-synthetic, senescent fibroblast populations that might contribute
to the formation of an activated tumour stroma. While this is a limitation in the deletion
given the results showing reduced pulmonary metastasis and tumour vascularization, the
absence of deleted proteins from the stroma of tumours, and the efficacy with which
knockout of CCN2 in synthetic fibroblasts using this promoter prevents the development
of fibrosis it is unlikely that senescent fibroblasts contribute to the activated tumour
stroma significantly. It is also of note that the deletion occurs in every synthetic
fibroblast in the body, not just those in the dermis that might be recruited to the stroma.
Because of this, it is possible that the deletion of CCN1 and CCN2 from the fibroblasts in
the lung is having some effect on the ability of cells to properly extravasate and survive
during metastasis. For example, it has been reported that increased periostin expression
from pulmonary fibroblasts is required for the survival of cancer stem cells which
extravasate into the lung to form pulmonary metastases (Malanchi, Santamaria-Martinez

139

et al. 2011). Given that deletion of CCN2 prevented expression of periostin in the
tumour stroma it is conceivable that it is having the same effect in pulmonary fibroblasts
and this lack of pulmonary periostin is influencing the amount of detected metastasis.
While I elected to use syngeneic implantation of tumour cells due to the effects of the
primary tumour on the microenvironment making it a closer mimic of the conditions of
metastasis in patients, the impact of primary tumour stroma CCN proteins and pulmonary
metastatic site CCN proteins could be deconvoluted in future studies by tail vein injection
of melanoma cells. A limitation in the micro-CT scans that determined tumour
vascularity is that the Microfil compound that was used to perfuse the tumours was
injected at a pressure that replicates physiological conditions. This means that any
vessels temporarily occluded, as occurs during cycling hypoxia, would not have been
detected (Muz, de la Puente et al. 2015). While this might be overcome by increasing the
injection pressure, that would likely result in the rupture of capillaries. Since the vascular
area of tumour sections showed the same reduction in mice with CCN2 deleted from their
fibroblasts as the vascular volume in micro-CT scans it is unlikely this significantly
altered the data collected.
Despite these limitations, it is clear that CCN1 and CCN2 in the tumour stroma play
important roles in the metastasis of melanoma. Future work to build off of these
discoveries should include tail vein injection of cells to determine the extent to which
CCN2 in the pulmonary metastatic microenvironment is contributing to metastasis
through periostin expression. Additionally, implantation of tumours into mice which
have been subjected to an experimental model of dermal fibrosis, such as bleomycin
injection or deletion of PTEN from the fibroblasts, would serve to increase evidence that
the fibrotic nature of the microenvironment is enhancing the metastasis of the tumour.
Finally since CCN1 and CCN2 are both important for metastasis, but seem to have
different functions it would be useful to find a therapy that targets both proteins at once.
Since elevated YAP has been shown to induce expression of CCN1 and CCN2, and a
widely clinically used drug (verteporfin) that prevents the activity of YAP has been
shown to be effective at controlling the progression of other cancers in mouse models it
would be an ideal first target for studies either administering verteporfin to mice
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implanted with melanoma, or implanting the cells into mice which have had YAP deleted
in their fibroblasts(Quan, Xu et al. 2014, Feng, Gou et al. 2016).
In summation, I found that both CCN1 and CCN2 in the tumour stroma contribute to the
metastasis of melanoma, but they do so in distinct ways. CCN1 is required for the
formation of organized collagen fibres which promote invasion and metastasis through
the transduction of mechanical stress onto cancer cells, through the activation of proinvasive phenotypes by integrin signaling, and by forming directional channels through
which the tumour cells can move. CCN2 is required for the activation of the tumour
stroma into a fibrotic environment containing myofibroblasts, and for the vascularization
of the tumour which provides easy access to the circulatory system for metastasis. Given
the stroma's demonstrated role in promoting the progression and metastasis of melanoma,
and its hypothesized role in contributing to therapy resistance by tumours, my findings
indicate that the CCN family of proteins represent an exciting potential therapeutic target
for the disruption of pro-tumourigenic stroma.
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